diff --git "a/data/ndd_v0.1.tsv" "b/data/ndd_v0.1.tsv" new file mode 100644--- /dev/null +++ "b/data/ndd_v0.1.tsv" @@ -0,0 +1,355 @@ +ndd_id patient_id tumor_tissue tumor_type_detail gene mutation_type mutation position mt_peptide wt_peptide length chromosome genomic_coord ref alt HLA response_type assay_type effector_origin stimulation_target presentation_method netmhcpan_rank netmhcstabpan_stability prime_rank bigmhc_im_score tap_score netchop_score dai_netmhcpan anchor_mutation eluted_ligand_match tcga_cancer_expression_tpm_median driver_status pubmed_id reference_name +NDDR-8Y7QQTRFWC-U GEXOATK7 Skin Skin Cutaneous Melanoma WDR46 SNV p.T227I 3 FLIYLDVSV FLTYLDVSV 9 6 33287207 G A HLA-A02:01 CD8 "ELISPOT, ICS" patient_TIL "peptide_pulsed_APC, tumor_cells" none 0.123 0.17 0.124 0.5000206 0.2 0.152263 -0.198450939 no 1 5.306262756328292 PMID:33303615 Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer +NDDR-2HJHFX0EFJ-0 GEXOATK7 Skin Skin Cutaneous Melanoma AHNAK SNV p.S4460F 1 FMPDFDLHL SMPDFDLHL 9 11 62526678 G A HLA-A02:01 CD8 "ELISPOT, ICS, multimer" patient_TIL peptide_pulsed_APC none 0.057 0.3 0.053 0.58284676 0.782 0.978539 -0.816761137 no 1 4.897806285758671 Other Tumor Driver PMID:33303615 Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer +NDDR-M2GXDWKP1W-D ZWHDI5GT Skin Skin Cutaneous Melanoma GNB5 SNV p.P377L 9 RVSTLRVSL RVSTLRVSP 9 15 52124519 G A HLA-B07:02 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.139 0.8 0.088 0.47644085 1.286 0.034531 -3.43537867 no 0 0.3897319869389105 PMID:33303615 Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer +NDDR-JRGCAYDCQA-S 6FHDB5EK Skin Skin Cutaneous Melanoma TRAPPC1 SNV p.R129G 4 FRSGLDSYV FRSRLDSYV 9 17 7930659 G C HLA-C06:02 CD8 "51Cr, HLA-block" patient_Tc_line "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.1 29 0.018 0.38020083 0.366 0.73499 -0.418710335 no 1 5.942411031709106 PMID:10582700 Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation +NDDR-VXMQ2DHCNY-F DAXCBTFA Skin Skin Cutaneous Melanoma TRAPPC1 SNV p.R129G 7 SELFRSGLDSY SELFRSRLDSY 11 17 7930659 G C HLA-B44:02 CD8 "51Cr, HLA-block" patient_Tc_line "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.266 0.4 0.581 0.052168835 3.04 0.763436 0.158546291 no 1 5.942411031709106 PMID:10582700 Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation +NDDR-AHCH9CD88T-A M4HZA63S Skin Skin Cutaneous Melanoma HERV-K-MEL SNV p.V102I 5 MLAVISCAV MLAVVSCAV 9 HLA-A02:01 CD8 "51Cr, HLA-block" patient_Tc_line "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 1.022 0.3 0.553 0.41658655 0.378 -0.068992871 no 0 PMID:12359761 A human endogenous retroviral sequence encoding an antigen recognized on Melanoma by cytolytic T lymphocytes +NDDR-MG2GYB7FKK-1 LFXUCEDT Skin Skin Cutaneous Melanoma PRDX5 SNV p.S79L 6 LLLDDLLVSI LLLDDSLVSI 10 11 64321032 C T HLA-A02:01 CD8 "51Cr, HLA-block, multimer" "patient_Tc_line, patient_TIL" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.171 0.4 0.046 0.5359305 0.624 0.954141 0.047913356 no 1 7.683650482276308 PMID:15695408 Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic Melanoma and targeted by CD8(+) T cells with a memory phenotype +NDDR-3Q45K91QR4-F D35NTCNS Skin Skin Cutaneous Melanoma MYO1B SNV p.E911K 1 KINKNPKYK EINKNPKYK 9 2 191414079 G A HLA-A03:01 CD8 "51Cr, HLA-block, multimer" "patient_Tc_line, patient_TIL" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.024 0.2 0.013 0.44635656 0.552 0.634706 -4.044512188 no 1 3.642421814668846 PMID:10064075 A natural cytotoxic T cell response in a spontaneously regressing human Melanoma targets a neoantigen resulting from a somatic point mutation +NDDR-4HG2AETK8S-9 V4WFIEVK Lung Non-Small Cell Lung Cancer (NSCLC) NFYC SNV p.Q241K 6 AQQITKTEV AQQITQTEV 9 HLA-B52:01 CD8 "51Cr, HLA-block" patient_Tc_line "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.454 7 0.023 0.16051857 0.728 0.260164044 no 0 3.0712220719161376 PMID:16287085 A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma +NDDR-BD6M2KY4NN-4 V4WFIEVK Lung Non-Small Cell Lung Cancer (NSCLC) NFYC SNV p.Q241K 5 QQITKTEV QQITQTEV 8 1 40769362 C A HLA-B52:01 CD8 "51Cr, HLA-block" patient_Tc_line "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.885 3 0.473 0.6644128 0.524 0.162851321 no 0 3.0712220719161376 PMID:16287085 A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma +NDDR-7SABVDNYFG-Y TSXDFNM6 Head & Neck Head and Neck Squamous Cell Carcinoma TP53 SNV p.Y220C 4 VVPCEPPEV VVPYEPPEV 9 HLA-A02:01 CD8 "51Cr, HLA-block" patient_Tc_line "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.751 9 1.073 0.3173151 0.454 0.687508 0.629941105 no 1 3.293914439591016 Tumor Driver PMID:17294448 Immunological characterization of missense mutations occurring within cytotoxic T cell defined p53 epitopes in HLA A0201 squamous cell carcinomas of the head and neck +NDDR-GSSA542C57-I 7LJZLSYK Skin Skin Cutaneous Melanoma ENTPD4 SNV p.P85L 7 ATDTNNLNVNY ATDTNNPNVNY 11 8 23447838 G A HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" none 2.391 4.5 1.282 0.36449605 2.864 0.96242 0.671222828 no 0 3.1196292036020346 PMID:33038342 Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction +NDDR-SGEY1B756Q-7 7LJZLSYK Skin Skin Cutaneous Melanoma TTC37 SNV p.A692V 6 YLDGKVVDY YLDGKAVDY 9 5 95520755 G A HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" none 3.937 35 11.33 0.3075591 2.426 -0.116625252 no 0 3.00543587954074 PMID:33038342 Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction +NDDR-WSV1MDSJB6-H TFT6DO6A Skin Skin Cutaneous Melanoma ARMT1 SNV p.P286L 2 FYGKTILWF FPGKTILWF 9 6 151468641 C T HLA-A24:02 CD8 "ELISPOT, ICS, multimer" PBMC_postVax peptide_pulsed_APC none 0.052 0.25 0.02 0.35181832 2.108 -4.193145147 no 0 2.896756166453227 PMID:30880120 Identification of a neoantigen epitope in a Melanoma patient with good response to anti-PD-1 antibody therapy +NDDR-XMMWH86R9X-E FNWFEVPE Cerebellum/Posterior fossa Medulloblastoma (pediatric) PDCD10 SNV p.A74P 4 IASPIKEL IASAIKEL 8 3 167687680 C G HLA-C12:02 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 0.234 2.5 3.957 0.14958204 0.99 0.48951 -1.082818708 no 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-BBEYF3X3HN-4 FNWFEVPE Cerebellum/Posterior fossa Medulloblastoma (pediatric) PDCD10 SNV p.A74P 10 LQTIKDIASPI LQTIKDIASAI 11 3 167687680 C G HLA-B52:01 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 7.046 0.4 10.695 0.000386612 0.728 0.897295 0.649003997 no 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-8FNTWKZDFG-Y FU5SPZUA Cerebellum/Posterior fossa Medulloblastoma (pediatric) TSEN54 SNV p.R472Q 2 AQMCISGF ARMCISGF 8 17 75523764 G A HLA-C12:03 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 22.864 1.2 33.066 0.003008314 3.142 0.307014 -0.193672219 yes 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-JDQYDNJXFT-A FU5SPZUA Cerebellum/Posterior fossa Medulloblastoma (pediatric) PCSK9 SNV p.V202F 11 DHREIEGRVMF DHREIEGRVMV 11 1 55052358 G T HLA-B18:01 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 0.158 12 1.548 0.14563482 2.264 0.536006 -2.522178045 no 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-0J9XF0AJTT-A FU5SPZUA Cerebellum/Posterior fossa Medulloblastoma (pediatric) PCSK9 SNV p.V202F 1 FTDFENVP VTDFENVP 8 1 55052358 G T HLA-C05:01 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 9.493 45 8.173 0.14667054 -0.474 0.405231 -0.296778883 no 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-0V67NT0BT2-D FU5SPZUA Cerebellum/Posterior fossa Medulloblastoma (pediatric) NEU2 SNV p.L234T 9 KTGEQRVVTL KTGEQRVVLL 10 2 233034587 G A HLA-C12:03 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 9.571 5.5 5.727 0.004257361 0.814 -0.381033667 yes 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-9A9KVDPVGD-V FU5SPZUA Cerebellum/Posterior fossa Medulloblastoma (pediatric) SVIL SNV p.D1285N 8 RTDVKAYNVT RTDVKAYDVT 10 HLA-C05:01 CD8 "ELISPOT, ICS, multimer" "patient_Tc_line, PBMC_pre" peptide_pulsed_APC none 12.052 31 3.575 0.17577124 -0.81 0.027018 -0.395570092 no 0 PMID:31351799 Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy +NDDR-NB93YAHBJ0-B 4V2JUJEQ Liver Hepatocellular Carcinoma C5orf42 SNV p.I1134K 13 DADILSETFQLLK DADILSETFQLLI 13 5 37201697 A T HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_Tc_line" peptide_pulsed_APC none 12.983 5.5 2.664 0.15842223 -1.879010447 no 0 PMID:31887370 Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma +NDDR-1YAP0FVN2C-U 4V2JUJEQ Liver Hepatocellular Carcinoma C5orf42 SNV p.I1134K 11 DILSETFQLLK DILSETFQLLI 11 5 37201697 A T HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_Tc_line" peptide_pulsed_APC none 3.101 1.8 0.978 0.09473962 0.296 -2.962619922 no 0 PMID:31887370 Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma +NDDR-0T85G4PK4N-4 4V2JUJEQ Liver Hepatocellular Carcinoma C5orf42 SNV p.I1134K 10 ILSETFQLLK ILSETFQLLI 10 5 37201697 A T HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_Tc_line" peptide_pulsed_APC none 0.675 0.5 0.762 0.07246435 0.432 -3.858778491 no 0 PMID:31887370 Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma +NDDR-JPW6QH0ZNW-D 4V2JUJEQ Liver Hepatocellular Carcinoma C5orf42 SNV p.I1134K 9 LSETFQLLK LSETFQLLI 9 5 37201697 A T HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_Tc_line" peptide_pulsed_APC none 0.544 1.2 0.28 0.12192804 0.316 -3.752958311 no 0 PMID:31887370 Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma +NDDR-AREYVJW6QB-T 3RRUMLDF Skin Skin Cutaneous Melanoma DCAKD SNV p.S199F 2 RFLEYLPLRF RSLEYLPLRF 10 17 45024533 G A HLA-A24:02 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.104 0.12 0.187 0.36792213 2.9 0.55062 -2.739598559 no 1 3.732597332974641 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-NPWGNEDF13-E G4ZPYEDM Skin Skin Cutaneous Melanoma DDX3X SNV p.E388K 4 FPKKIQMLA FPKEIQMLA 9 X 41345316 G A HLA-B56:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.006 0.07 0.347 0.83115304 -1.374 0.920179 0.405465108 no 0 4.161427619593944 Tumor Driver PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-1RZ65VX580-B G4ZPYEDM Skin Skin Cutaneous Melanoma ITGA9 SNV p.L548P 7 VTEKLQPTY VTEKLQLTY 9 3 37542539 T C HLA-A01:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.02 0.12 0.02 0.28144857 2.714 0.946856 1.609437912 no 0 1.3090999275179485 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-5NDTKW9WVC-U G6DBM54G Skin Skin Cutaneous Melanoma VPS16 SNV p.S404F 5 LRAAFFGKCF LRAASFGKCF 10 20 2862814 C T HLA-B27:05 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 2.327 0.8 0.612 0.41129395 2.934 0.412664 -0.018731923 no 0 3.7031671368041055 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-MHSQEBMGSW-D G6DBM54G Skin Skin Cutaneous Melanoma CIT SNV p.P2056L 4 VRTLLSQVNK VRTPLSQVNK 10 12 119690296 G A HLA-B27:05 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.829 0.4 1.059 0.6598468 0.756 0.817271 0.57818275 no 0 0.6508097074039529 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-M431P5K4KM-3 G6DBM54G Skin Skin Cutaneous Melanoma CASP1 SNV p.P172S 8 WRNILLLSLH WRNILLLPLH 10 11 105041480 G A HLA-B27:05 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 2.113 1.2 0.462 0.7958803 -0.566 -0.025234984 no 0 2.918489810532816 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-YZD3GSV3PV-C F3XRZQLP Skin Skin Cutaneous Melanoma FAM200A SNV p.S116F 9 IPLSDNTIF IPLSDNTIS 9 7 99548061 G A HLA-B35:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.049 0.12 0.039 0.5422627 1.964 0.042772 -4.541121341 yes 0 1.9769849273236493 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-QFKBAJAWPA-S F3XRZQLP Skin Skin Cutaneous Melanoma GRIN2B SNV p.E1104K 5 REFDKIELAY REFDEIELAY 10 12 13563928 C T HLA-B41:02 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.527 2.5 0.137 0.47341612 3.384 0.977014 -0.564753017 no 0 -7.861447624847352 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-3FYD6RDVNQ-7 F3XRZQLP Skin Skin Cutaneous Melanoma TBX4 SNV p.S271F 5 YPVIFKSIM YPVISKSIM 9 17 61480110 C T HLA-B35:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.083 0.08 0.076 0.8534652 -0.268 0.949069 0.170345366 yes 0 -5.357023508242532 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-J3PXJHBAC2-D URSBQAUG Skin Skin Cutaneous Melanoma FAM50B SNV p.E78K 7 DMKARQKALV DMKARQEALV 10 6 3850043 G A HLA-B08:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.843 3 3.24 0.6509104 0.1 0.521495 0.064934013 yes 0 2.637760851362445 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-5G69MS9MJJ-0 3RRUMLDF Skin Skin Cutaneous Melanoma ACPP SNV p.E34K 1 KLKFVTLVF ELKFVTLVF 9 3 132317556 G A HLA-A24:02 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.978 1.7 0.106 0.2514855 2.69 -0.884713534 no 0 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-6KW890FEY0-B 3RRUMLDF Skin Skin Cutaneous Melanoma ACPP SNV p.E34K 1 KLKFVTLVF ELKFVTLVF 9 3 132317556 G A HLA-B15:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.049 0.2 0.002 0.3059785 2.69 -2.043073898 no 0 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-BGT2WPZEN8-J F3XRZQLP Skin Skin Cutaneous Melanoma COL22A1 SNV p.D291N 7 FPQGLPNEY FPQGLPDEY 9 8 138826756 C T HLA-B35:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC none 0.003 0.09 0.016 0.56636214 2.026 0.818258 0 yes 0 0.9192631801181528 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-51YCQP8A9M-3 F3XRZQLP Skin Skin Cutaneous Melanoma COL22A1 SNV p.D291N 3 LPNEYAFVTT LPDEYAFVTT 10 8 138826756 C T HLA-B35:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 4.521 1 0.237 0.36414808 -1.422 0.05056 0.028720843 yes 0 0.9192631801181528 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-B7GMHB69XA-S F3XRZQLP Skin Skin Cutaneous Melanoma COL22A1 SNV p.D291N 3 LPNEYAFVT LPDEYAFVT 9 8 138826756 C T HLA-B35:01 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC TMC 0.923 0.5 0.19 0.71816474 -1.422 0.499 -0.327767067 yes 0 0.9192631801181528 PMID:28678778 An immunogenic personal neoantigen vaccine for patients with Melanoma +NDDR-MSZN302K7F-X DZL67UZM Skin Skin Cutaneous Melanoma CDC37L1 SNV p.P186L 6 FLSDHLYLV FLSDHPYLV 9 9 4697144 C T HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.002 0.01 0.001 0.73414487 0.054 0.947568 0 no 1 1.3965157022711483 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-G695BNZBRH-Z DZL67UZM Skin Skin Cutaneous Melanoma DOPEY2 SNV p.R365C 4 KPFCVLISL KPFRVLISL 9 21 36214520 C T HLA-B07:02 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.239 0.12 0.015 0.6494463 0.756 1.97995599 no 0 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-A19KEFTKZ2-D DZL67UZM Skin Skin Cutaneous Melanoma FLNA SNV p.P369L 9 AGQHIAKSLF AGQHIAKSPF 10 X 154366430 G A HLA-B44:02 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 4.19 18 1.837 0.036542095 2.526 0.44498 -0.685119821 no 0 7.162794730001245 Other Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-M93AXPJXAK-1 DZL67UZM Skin Skin Cutaneous Melanoma FLNA SNV p.P369L 6 HIAKSLFEV HIAKSPFEV 9 X 154366430 G A HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.107 0.4 0.045 0.38504964 0.376 0.884259 -0.655047334 no 1 7.162794730001245 Other Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-TSWQ8ED6V6-H DZL67UZM Skin Skin Cutaneous Melanoma KMT2C SNV p.P1984S 3 KPSDTPRPVM KPPDTPRPVM 10 7 152181961 G A HLA-B07:02 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.015 0.1 0.161 0.5348725 -0.126 0.858985 -1.120591195 no 0 1.90735193605836 Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-2YDKRK2AD9-K NGE5BUYC Skin Skin Cutaneous Melanoma TTBK2 SNV p.S1088L 9 RPHHDQRSL RPHHDQRSS 9 15 42745988 G A HLA-B07:02 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.008 0.05 0.1 0.729896 0.654 0.118015 -4.777020443 no 0 0.1116984543301548 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-VAPV22ZYG6-H LC3W5VRX Skin Skin Cutaneous Melanoma KIF26B SNV p.N256S 2 SSYTGFANK SNYTGFANK 9 1 245367135 A G HLA-A11:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.007 0.3 0.006 0.3342279 0.99 0.970843 -4.33073334 no 0 1.1247087440778083 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-KWE7NJQDW7-I LYXKV47S Skin Skin Cutaneous Melanoma SPOP SNV p.N147I 7 FLLDEAIGL FLLDEANGL 9 17 49619021 T A HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.009 0.8 0.042 0.64465654 0.738 0.943178 -0.893817876 no 1 2.900451304280764 Other Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-3W2VQMDDEP-6 N6T2LYFN Skin Skin Cutaneous Melanoma RETSAT SNV p.P546S 8 HDLGRLHSC HDLGRLHPC 9 2 85343696 G A HLA-B37:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 1.188 13 0.017 0.9232992 -0.304 0.026627 -0.520375835 no 0 4.736423449262938 Other Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-GFWC1867QW-D N6T2LYFN Skin Skin Cutaneous Melanoma RETSAT SNV p.P546S 2 HSCVMASLR HPCVMASLR 9 2 85343696 G A HLA-A68:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.84 0.3 0.065 0.37042683 1.5 0.646453 -1.071257405 no 0 4.736423449262938 Other Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-KYVW6EZ6RX-E OKQRI23E Skin Skin Cutaneous Melanoma NARFL SNV p.E62K 1 KSQREEVRR ESQREEVRR 9 HLA-A31:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.411 1.3 0.683 0.025451975 1.666 -2.183066976 no 0 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-NFN8N8118Y-F VU5HBL4S Skin Skin Cutaneous Melanoma PPFIA4 SNV p.S709N 4 MRMNQGVCC MRMSQGVCC 9 1 203053848 G A HLA-B39:06 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.418 0.09 3.039 0.9724981 0.486 0.033837 0.426009637 no 0 -0.786497185381495 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-73G4NR2F2Q-7 LYXKV47S Skin Skin Cutaneous Melanoma CDK4 SNV p.R24L 2 ALDPHSGHFV ARDPHSGHFV 10 12 57751647 C A HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.085 1.2 0.065 0.4697877 0.228 0.668099 -4.919637372 no 1 4.89146952891671 Tumor Driver PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-X3SEE1T450-B FRMBI3H3 Skin Skin Cutaneous Melanoma CLINT1 SNV p.T472I 4 VSKILPSTW VSKTLPSTW 9 5 157789479 G A HLA-B57:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.006 0.4 0.003 0.8338965 1.018 0.903586 0 no 0 3.647901429523587 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-19YD017ZK3-E FRMBI3H3 Skin Skin Cutaneous Melanoma COX7A2 SNV p.A84V 5 GVADVLLYR GVADALLYR 9 6 75240339 G A HLA-A11:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC none 0.021 0.3 0.004 0.74445856 1.534 0.159054 -0.619039208 no 0 5.434168171613791 PMID:28678784 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer +NDDR-B1DKTHN336-H 5DJDBZPW Skin Skin Cutaneous Melanoma SYTL4 SNV p.S363F 6 GRIAFFLKY GRIAFSLKY 9 X 100687163 G A HLA-B27:05 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC MS 0.009 0.4 0.001 0.914394 3.272 0.977758 0.117783036 no 1 -2.57304527896216 PMID:27869121 Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry +NDDR-VZ6AX01GXJ-0 5DJDBZPW Skin Skin Cutaneous Melanoma NCAPG2 SNV p.P333L 2 KLILWRGLK KPILWRGLK 9 7 158680743 G A HLA-A03:01 CD8 ELISPOT patient_TIL peptide_pulsed_APC MS 0.184 0.4 0.122 0.43575552 0.762 0.861472 -3.519785246 no 1 2.653481961494572 PMID:27869121 Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry +NDDR-PBXJS7YJDT-A 5DJDBZPW Skin Skin Cutaneous Melanoma AKAP6 SNV p.M1482I 6 KLKLPIIMK KLKLPMIMK 9 14 32822259 G C HLA-A03:01 CD8 ELISPOT patient_TIL peptide_pulsed_APC MS 0.006 0.12 0.001 0.46870586 0.62 0.968833 -0.15415068 no 1 -0.3858191584351662 PMID:27869121 Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry +NDDR-WKQY9KFRV9-K PKPFBJDF Skin Skin Cutaneous Melanoma NOP16 SNV p.P169L 9 SPGPVKLEL SPGPVKLEP 9 5 176384171 G A HLA-B07:02 CD8 ELISPOT patient_TIL peptide_pulsed_APC MS 0.011 0.7 0.028 0.2350611 0.112 -4.500819262 no 1 2.721894946966146 PMID:27869121 Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry +NDDR-C98AVT8VA9-K I4HS6WN2 Skin Skin Cutaneous Melanoma CSNK1A1 SNV p.S27L 2 GLFGDIYLA GSFGDIYLA 9 5 149550885_149550886 TC CT HLA-A02:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.052 1.5 0.046 0.5908489 -0.414 0.312295 -4.006283684 no 1 3.0297071395965185 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-FF8XNFEPVF-X 74LV6E74 Skin Skin Cutaneous Melanoma MATN2 SNV p.E226K 1 KTLTSVFQK ETLTSVFQK 9 8 97931486 G A HLA-A11:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.004 0.01 0.001 0.44113854 0.686 0.926989 -3.102342009 no 1 2.15613714562124 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-894FCPT0FK-1 74LV6E74 Skin Skin Cutaneous Melanoma CDK12 SNV p.E928K 5 CILGKLFTK CILGELFTK 9 7 40063036 G A HLA-A11:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.279 1.1 0.021 0.14316015 0.56 0.34099 -0.327212911 no 1 2.5695493966620635 Tumor Driver PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-AYRXPFMZNE-W 74LV6E74 Skin Skin Cutaneous Melanoma CDK12 SNV p.E928K 5 CILGKLFTKK CILGELFTKK 10 7 40063036 G A HLA-A11:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 1.908 1.2 0.466 0.20398991 0.56 0.794302 0.048868784 no 0 2.5695493966620635 Tumor Driver PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-YRY5RYAEAT-A I4HS6WN2 Skin Skin Cutaneous Melanoma CSNK1A1 SNV p.S27L 2 GLFGDIYLAI GSFGDIYLAI 10 5 149550885_149550886 TC CT HLA-A02:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.369 0.8 0.185 0.5734593 0.656 0.921601 -3.064454106 no 1 3.0297071395965185 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-EMJNAQ3KAZ-G I4HS6WN2 Skin Skin Cutaneous Melanoma HAUS3 SNV p.T160A 7 ILNAMIAKI ILNAMITKI 9 4 2240469 T C HLA-A02:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.43 0.5 0.15 0.64783394 0.322 0.879551 0.75057923 no 1 0.5219504898143807 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-BGR5R73328-J 74LV6E74 Skin Skin Cutaneous Melanoma MATN2 SNV p.E226K 1 KTLTSVFQKK ETLTSVFQKK 10 8 97931486 G A HLA-A11:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.054 0.01 0.069 0.44877782 0.686 0.963817 -2.580497374 no 0 2.15613714562124 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-545JRB33M5-G J5PM7M2Y Skin Skin Cutaneous Melanoma PLEKHM2 SNV p.H1005Y 10 LTDDRLFTCY LTDDRLFTCH 10 1 15732428 C T HLA-A01:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.009 0.01 0.006 0.6954793 2.652 0.412145 -4.33365305 no 0 5.051104136934164 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-F477MEXVTB-T I4HS6WN2 Skin Skin Cutaneous Melanoma GAS7 SNV p.H225Y 9 SLADEAEVYL SLADEAEVHL 10 17 9934186 G A HLA-A02:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.095 2.5 0.045 0.34322897 1.054 0.969244 -0.408967739 no 1 5.458258899654696 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-1NGBH26P25-G J5PM7M2Y Skin Skin Cutaneous Melanoma PPP1R3B SNV p.P176H 5 YTDFHCQYV YTDFPCQYV 9 8 9141125 G T HLA-A01:01 CD8 "ELISPOT, ICS" patient_TIL peptide_pulsed_APC none 0.224 1.3 0.005 0.68494403 -0.158 0.901694 -0.117783036 no 1 2.600530749761819 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-3397S1P89B-T J5PM7M2Y Skin Skin Cutaneous Melanoma PPP1R3B SNV p.P176H 5 YTDFHCQYVK YTDFPCQYVK 10 8 9141125 G T HLA-A01:01 CD8 "ELISPOT, ICS" patient_TIL "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.841 1.2 0.145 0.48095936 -0.008 0.912707 0.144290612 no 1 2.600530749761819 PMID:23644516 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells +NDDR-4H8V6XSZ4F-X 6K4YGFNF Skin Skin Cutaneous Melanoma KIF16B SNV p.L1009P 2 APARLERRHSA ALARLERRHSA 11 20 16378976 A G HLA-B07:02 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.459 0.7 2.211 0.022523178 -0.818 0.78183 -3.67124115 no 0 1.9052529727866243 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-1C3G4QSC15-G 6K4YGFNF Skin Skin Cutaneous Melanoma FLNA SNV p.R2049C 1 CVRVSGQGL RVRVSGQGL 9 X 154353082 G A HLA-B07:02 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 1.384 1.8 0.386 0.06314378 1.114 0.953143 2.305479451 no 0 7.162794730001245 Other Tumor Driver PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-Y4RAXRTAQJ-0 OGN36M6H Skin Skin Cutaneous Melanoma KIF1BP SNV p.P246S 4 AYHSIEWAI AYHPIEWAI 9 HLA-A24:02 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.206 0.2 0.121 0.15551695 1.012 0.873528873 no 0 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-1N2HY69Q10-B OGN36M6H Skin Skin Cutaneous Melanoma KIF1BP SNV p.P246S 6 HNAYHSIEWA HNAYHPIEWA 10 HLA-B38:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 33.333 39 3.253 0.028419605 -0.71 0.165808485 no 0 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-D73BQ8XHHP-6 OGN36M6H Skin Skin Cutaneous Melanoma KIF1BP SNV p.P246S 7 EHNAYHSIEWA EHNAYHPIEWA 11 HLA-B38:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 3.934 31 3.421 0.070759766 -1.148 0.122049879 no 0 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-ZQ6KEKP7NG-Y OGN36M6H Skin Skin Cutaneous Melanoma KIF1BP SNV p.P246S 5 NAYHSIEWAI NAYHPIEWAI 10 HLA-C12:03 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 7.444 11 3.759 0.021690775 1.216 0.500667825 yes 0 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-KQX0BHDE2V-C OGN36M6H Skin Skin Cutaneous Melanoma KIF1BP SNV p.P246S 3 YHSIEWAI YHPIEWAI 8 10 69005862 C T HLA-B38:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.184 0.5 0.142 0.4799058 0.332 -0.240385358 no 0 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-WYJW76M06R-8 TOGZJCOT Skin Skin Cutaneous Melanoma PDS5A SNV p.Y1000F;H1007Y "1,8" FVVPYMIYLL YVVPYMIHLL 10 HLA-C03:03 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 4.104 4.5 0.127 0.08873232 0.976 0.971609 1.044545067 yes 0 3.1924296896282964 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-XJ3RMEC41A-S TOGZJCOT Skin Skin Cutaneous Melanoma MAGEA6 SNV p.E168K 1 KVDPIGHVY EVDPIGHVY 9 X 152767149 C T HLA-A01:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.011 0.02 0.006 0.53820276 2.85 0.975792 0.606135804 no 0 2.919135799116131 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-BS3218G751-C TOGZJCOT Skin Skin Cutaneous Melanoma MAGEA6 SNV p.E168K 1 KVDPIGHVYIF EVDPIGHVYIF 11 HLA-C05:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.207 20 0.147 0.21876486 2.46 0.972332 -1.486205272 no 0 2.919135799116131 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-YXV2AQ4573-E TOGZJCOT Skin Skin Cutaneous Melanoma MAGEA6 SNV p.E168K 3 LMKVDPIGHVY LMEVDPIGHVY 11 HLA-B15:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.178 0.04 0.557 0.09490901 3.084 0.975792 -1.54804052 no 0 2.919135799116131 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-0CQM64X89C-U TOGZJCOT Skin Skin Cutaneous Melanoma MED13 SNV p.P1691S 6 SVQIISCQY SVQIIPCQY 9 HLA-A30:02 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.122 2.5 0.031 0.99646705 3.044 0.965587 0.541341168 no 0 2.533189523071888 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-8V8HWA94GP-6 TOGZJCOT Skin Skin Cutaneous Melanoma MED13 SNV p.P1691S 5 VQIISCQY VQIIPCQY 8 17 61961773 G A HLA-A30:02 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 1.365 4 11.228 0.9654861 3.326 0.965587 0.328300587 no 0 2.533189523071888 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-R8DTB8R876-H TOGZJCOT Skin Skin Cutaneous Melanoma MED13 SNV p.P1691S 5 VQIISCQY VQIIPCQY 8 17 61961773 G A HLA-B15:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.34 0.12 0.377 0.39582428 3.326 0.965587 0.10209787 no 0 2.533189523071888 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-NG120S2XBY-F TOGZJCOT Skin Skin Cutaneous Melanoma MED13 SNV p.P1691S 7 VSVQIISCQY VSVQIIPCQY 10 HLA-A30:02 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.491 3.5 1.446 0.9920119 3.218 0.965587 -0.085822619 no 0 2.533189523071888 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-HHJP6E4WJE-W TOGZJCOT Skin Skin Cutaneous Melanoma MED13 SNV p.P1691S 7 VSVQIISCQY VSVQIIPCQY 10 HLA-A01:01 CD8 "multimer, ELISPOT" "PBMC_pre, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.715 0.12 1.623 0.058954675 3.218 0.965587 0.035590945 no 0 2.533189523071888 PMID:26901407 Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients +NDDR-NS03YKG0DA-S DYEDTPM2 Ovary Ovarian Cancer HLA-DRB1 SNV p.I248L 8 FLGAGLFLYF FLGAGLFIYF 10 6 32580767 T G HLA-A02:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 5.948 4 0.317 0.38981387 1.956 0.838477 0.003536846 no 0 8.017806688167449 Other Tumor Driver PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-NATBNFYEAK-1 YQSS3IYL Ovary Ovarian Cancer HS6ST1 SNV p.S405I 4 DYMIHIIEKW DYMSHIIEKW 10 2 128268184 C A HLA-A23:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.328 0.9 0.215 0.5965645 0.846 0.959502 0.291755398 no 0 4.582285020651232 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-BHHDNDR6ZQ-7 VMHDDH4X Ovary Ovarian Cancer COPG2 SNV p.T37I 1 IPINPRRCL TPINPRRCL 9 7 130666910 G A HLA-B07:02 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.025 0.06 0.434 0.80835074 0.486 0.764573 0.083381609 no 0 3.1538863840856237 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-FQESYTA52V-C BFEZW33V Ovary Ovarian Cancer EBF4 SNV p.I510S 2 ASMPSSPPL AIMPSSPPL 9 20 2755627 T G HLA-B15:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 2.235 1.8 2.416 0.009759571 1.436 0.957767 0.54959901 no 0 2.825521075205641 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-PZTTJ71JFS-9 BFEZW33V Ovary Ovarian Cancer TRIM26 SNV p.G497W 5 LDYEWGTVTF LDYEGGTVTF 10 6 30186007 C A HLA-B15:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 4.054 5.5 0.619 0.4396839 2.696 0.975767 0.273800899 no 1 4.100178731752236 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-1V9MW00YAR-8 BFEZW33V Ovary Ovarian Cancer DCHS1 SNV p.P141L 9 VADINDHAL VADINDHAP 9 HLA-C03:03 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.078 11 0.047 0.6778647 0.722 0.050902 -5.09838002 yes 0 0.4893374088893816 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-RABCTRZ18B-T TKJU56TT Ovary Ovarian Cancer SEPT9 SNV p.R289H 7 SILEQMHRK SILEQMRRK 9 HLA-A11:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.02 0.6 0.128 0.18997331 0.682 -1.848454813 no 1 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-81PF6HAJE6-H Q2ITNIFI Ovary Ovarian Cancer PDPN SNV p.G222C 3 FICAIIVVV FIGAIIVVV 9 1 13614365 G T HLA-A02:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 1.217 0.4 0.024 0.68458986 0.196 0.680153 0.893544016 no 0 2.404058397054795 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-WAWJVEYCNM-3 Q2ITNIFI Ovary Ovarian Cancer KIR2DS4 SNV p.I7S 1 SMACVGFFL IMACVGFFL 9 HLA-A02:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 1.021 1.9 0.068 0.3632761 1.164 0.623868 -0.075436319 no 0 -5.058893689053568 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-S6WF724CZW-D TRB3HZII Ovary Ovarian Cancer HHAT SNV p.L75F 8 KQWLVWLFL KQWLVWLLL 9 1 210387531 C T HLA-A02:06 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 1.055 5.5 0.42 0.2886589 1.67 0.883886 0.211364852 no 1 -0.3113272616608571 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-B9FTPHZX9N-4 GNQ75CJK Ovary Ovarian Cancer USP47 SNV p.V170L 5 TSDYLSQSY TSDYVSQSY 9 11 11892058 G C HLA-A01:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.002 0.4 0.004 0.25253442 2.636 0.971324 0 no 0 0.7376002403722687 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-249DDXWAEX-E Q2CMUUIO Ovary Ovarian Cancer ZCCHC11 SNV p.P1265H 8 GRKLFGTHF GRKLFGTPF 9 1 52445815 G T HLA-B27:05 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.083 1 0.002 0.8584188 2.74 -1.036480508 no 0 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-7HYKQEP4CF-X Q2CMUUIO Ovary Ovarian Cancer TP53 SNV p.A159V 4 RVRVMAIYK RVRAMAIYK 9 17 7675136 G A HLA-A11:01 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.275 0.12 0.109 0.36357912 0.902 0.656203 0.682297165 no 1 4.5900989584528045 Other Tumor Driver PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-P8JN2PCQXP-6 Q2CMUUIO Ovary Ovarian Cancer OR2T3 SNV p.C132Y 2 VYRPLHYPLL VCRPLHYPLL 10 1 248473745 G A HLA-C07:02 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.997 17 0.801 0.9149756 1.256 0.853258 -0.911263069 no 0 -9.965784284662089 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-8KVBFCA09D-V 4DKUZH62 Ovary Ovarian Cancer ODZ3 SNV p.A2490V 9 GAQSWLWFV GAQSWLWFA 9 4 182799720 C T HLA-A02:11 CD8 "ELISPOT, ICS, multimer" PBMC_pre peptide_pulsed_APC none 0.923 0.7 0.142 0.9752533 0.216 -1.199847296 yes 0 PMID:29545564 Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer +NDDR-KZ1CVJYBN3-E 65DW3BKE Brain Glioblastoma (GBM) ARHGAP35 SNV p.T1313M 1 MVNTVAGAMK TVNTVAGAMK 10 19 46989577 C T HLA-A68:01 CD8 "ELISPOT, ICS" "PBMC_postVax, patient_Tc_line" peptide_pulsed_APC none 0.796 0.6 0.36 0.11304907 0.424 0.576836 0.325229145 no 0 3.854868211998318 Other Tumor Driver PMID:30568305 Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial +NDDR-C7G64WM1VP-6 65DW3BKE Brain Glioblastoma (GBM) SLX4 SNV p.R1814H 6 TTAATHREK TTAATRREK 9 16 3582406 C T HLA-A68:01 CD8 "ELISPOT, ICS" "PBMC_postVax, patient_Tc_line" peptide_pulsed_APC none 0.19 1.3 0.065 0.060915194 0.502 0.330413 -0.463402945 no 0 1.1642972325758092 PMID:30568305 Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial +NDDR-453FFPEY00-B YG2NSK3U Brain Glioblastoma (GBM) IDH1 SNV p.R132H 10 GWVKPIIIGH GWVKPIIIGR 10 2 208248388 C T HLA-B58:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 29.107 49 20.4 0.019775497 -0.336 0.868231 -0.230243719 yes 0 5.0249227509655015 Tumor Driver PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-W3ZRQB9QB9-K TBH3PNXF Brain Glioblastoma (GBM) SLC44A2 SNV p.L204M 4 ITDMVEGAKK ITDLVEGAKK 10 HLA-A03:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 2.002 2.5 1.811 0.17725703 0.114 0.373603 -0.165362037 no 0 5.438249584664644 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-Q35B4A9CVQ-7 MYK5YWYV Brain Glioblastoma (GBM) RFX1 SNV p.T324M 2 YMQTASTSYY YTQTASTSYY 10 HLA-A01:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 0.332 1 0.059 0.13062443 2.824 0.966927 2.22161603 no 0 1.4104223324555083 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-0EZ996H7KA-S MYK5YWYV Brain Glioblastoma (GBM) EPHB3 SNV p.R677W 7 YTERQRWDF YTERQRRDF 9 HLA-A01:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 0.615 5 0.469 0.021731572 2.126 0.088796 -0.998956638 no 0 2.6118802265891805 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-A9KQRJ0YTC-U ZLZLTBFT Brain Glioblastoma (GBM) NUCB1 SNV p.V300M 8 RLRMREHMMK RLRMREHVMK 10 HLA-A03:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 0.167 0.15 0.361 0.35916224 0.784 0.947325 -0.247982203 no 0 5.924214386698314 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-33JMV261X3-E KZYSWBUF Brain Glioblastoma (GBM) ATF7 SNV p.R131H 1 HPGSLPLHL RPGSLPLHL 9 HLA-B53:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 0.063 1.9 0.016 0.41726562 -0.042 0.975242 -2.00533357 no 0 1.5754683550479136 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-GFWDJT4ZT7-I KZYSWBUF Brain Glioblastoma (GBM) EPS15 SNV p.T217M 9 LVPPSKRKMWV LVPPSKRKTWV 11 HLA-A68:02 CD8 ICS PBMC_postVax peptide_pulsed_APC none 6.879 20 19.909 0.24659498 0.456 0.732632 -0.150092866 no 0 4.122713875214625 Other Tumor Driver PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-AVMMMGVYAD-V E2RY6NVI Brain Glioblastoma (GBM) PCDH19 SNV p.A470T 6 NNTPGTYLLSV NNTPGAYLLSV 11 HLA-A02:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 26.868 18 4.418 0.20546159 0.362 0.969457 0.004887613 no 0 1.228014630177265 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-7CFRJFW87P-6 E2RY6NVI Brain Glioblastoma (GBM) C14orf102 SNV p.P979L 2 YLLAPLREAL YPLAPLREAL 10 HLA-A02:01 CD8 "ICS, multimer" PBMC_postVax peptide_pulsed_APC none 0.477 1.3 1.706 0.35997468 0.844 -0.984752365 no 0 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-44QS1THAG3-E F3UNKL3Y Brain Glioblastoma (GBM) RBKS SNV p.T95A 7 KQNDISAEF KQNDISTEF 9 HLA-B15:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 0.004 0.02 0.002 0.29537684 2.718 0.966161 0.287682072 no 0 0.3331357279025131 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-6J2G3WKA08-J GVYOONV4 Brain Glioblastoma (GBM) SLC9A6 SNV p.N572I 10 SAWLFRMWYI SAWLFRMWYN 10 HLA-A02:01 CD8 ICS PBMC_postVax peptide_pulsed_APC none 13.515 6 1.186 0.17660923 1.012 0.022848 -1.778226455 no 0 2.120798798361302 PMID:30733620 Actively personalized vaccination trial for newly diagnosed glioblastoma +NDDR-EDQDWAWTP4-F PFMINZ56 Breast Breast Cancer ECPAS SNV p.S186F 10 MPYGYVLNEF MPYGYVLNES 10 9 111437072_111437073 CA TT HLA-B35:01 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" "peptide_pulsed_APC, TMC_minigene" TMC 0.056 0.05 0.018 0.47865343 2.356 0.422068 -4.303582351 yes 0 4.401606288396909 PMID:29867227 Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer +NDDR-Y3TJTRGEMA-S PFMINZ56 Breast Breast Cancer CADPS2 SNV p.R1266H 8 TYDTVHRHL TYDTVHRRL 9 7 122320259 C T HLA-C04:01 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" "peptide_pulsed_APC, TMC_minigene" TMC 0.006 25 0.001 0.66004187 0.732 0.958242 -0.287682072 no 0 3.089786043720456 PMID:29867227 Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer +NDDR-9MF2CZ9EEC-U 6TP4IBLE Skin Skin Cutaneous Melanoma PORCN SNV p.H346Y 8 LLHGFSFYL LLHGFSFHL 9 X 48515902 C T HLA-A02:01 CD8 "multimer, 51Cr" "PBMC_pre, PBMC_postVax, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.086 0.15 0.015 0.73443514 1.068 0.977941 0.059898142 no 1 1.8863837225668296 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-7HFGTRT2KG-Y 6TP4IBLE Skin Skin Cutaneous Melanoma AKAP9 SNV p.L947F 5 RLSDFSEQL RLSDLSEQL 9 7 92002801 C T HLA-A02:01 CD8 "multimer, 51Cr" "PBMC_pre, PBMC_postVax, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.024 0.4 0.069 0.49961323 1.168 0.977036 -0.223143551 no 1 2.05500471197816 Other Tumor Driver PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-R6WWVF6EQ6-H 6TP4IBLE Skin Skin Cutaneous Melanoma RASAL2 SNV p.P637S 4 IMSSSLFNL IMSPSLFNL 9 1 178452552 C T HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.236 0.6 0.066 0.30667874 1.032 0.969002 1.352957941 no 1 1.3316192229287085 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-108MYSE1VC-U 6TP4IBLE Skin Skin Cutaneous Melanoma CDKN2A SNV p.P114L 2 LLVDLAEEL LPVDLAEEL 9 9 21971018 G A HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.1 2.5 0.174 0.4786835 1.164 0.957983 -4.712319102 no 0 1.258458621457592 Tumor Driver PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-1G2Z2Z3NBX-E 6TP4IBLE Skin Skin Cutaneous Melanoma PDE7B SNV p.G113R 1 RMWDFDIFL GMWDFDIFL 9 6 136149105 G A HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.022 0.09 0.005 0.7197922 1.63 0.968043 -0.127833372 no 0 -1.260168451057003 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-SEA7CN1KAX-E 6TP4IBLE Skin Skin Cutaneous Melanoma GCN1L1 SNV p.P274L 6 SLLRSLENV SLLRSPENV 9 12 120177464 G A HLA-A02:01 CD8 "multimer, 51Cr" "PBMC_pre, PBMC_postVax, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.06 0.4 0.081 0.54666144 0.416 -0.559615788 no 1 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-EZBD3HKP1K-1 6TP4IBLE Skin Skin Cutaneous Melanoma SOCS6 SNV p.P134L 9 SLRSHHYSL SLRSHHYSP 9 18 70325069 C T HLA-B08:01 CD8 "multimer, 51Cr" "PBMC_pre, PBMC_postVax, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.006 0.6 0.023 0.48079756 1.118 0.409931 -5.37296091 yes 1 3.0672944671553912 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-5GDBWJVZ1H-Z 6TP4IBLE Skin Skin Cutaneous Melanoma POGK SNV p.P46L 3 WVLALFDEV WVPALFDEV 9 1 166846616 C T HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" "peptide_pulsed_APC, TMC_minigene" none 3.02 4.5 0.733 0.34715846 0.314 0.288239 -0.050995237 no 0 3.563060296867492 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-T0AFTDJ9PD-V 6TP4IBLE Skin Skin Cutaneous Melanoma ZDBF2 SNV p.S2228L 3 YILKYSVFL YISKYSVFL 9 2 206311211 C T HLA-A02:01 CD8 "multimer, 51Cr" "PBMC_pre, PBMC_postVax, patient_TIL" "peptide_pulsed_APC, TMC_minigene" TMC 0.193 0.5 0.027 0.61301035 0.96 0.963955 -0.179727522 no 1 -0.664534160245007 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-47041KC807-I 6TP4IBLE Skin Skin Cutaneous Melanoma GAS7 SNV p.S270F 1 FLGEAWAQV SLGEAWAQV 9 17 9934242 G A HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.055 0.9 0.392 0.5921987 -0.264 0.969671 -0.828948722 no 0 5.458258899654696 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-JV00FYYZJR-8 6TP4IBLE Skin Skin Cutaneous Melanoma PNPLA4 SNV p.P100S 3 ILSPSAHEL ILPPSAHEL 9 X 7921826 G A HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.024 1.4 0.196 0.43104225 0.922 0.976745 -0.432864082 no 0 2.4620915882703924 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-F4XKDRRJHC-U OHRF7YEV Skin Skin Cutaneous Melanoma SIPA1L3 SNV p.S893F 5 ILGIFNEFV ILGISNEFV 9 19 38119692 C T HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.531 1.2 0.207 0.5177895 -0.036 0.159378 -0.479842078 no 1 1.747236986219996 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-ENN0NBG9ZX-E OHRF7YEV Skin Skin Cutaneous Melanoma ERCC6L SNV p.V476I 7 KIYRRQIFK KIYRRQVFK 9 X 72206972 C T HLA-A11:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.037 0.12 0.193 0.35617954 1.114 0.56284 -0.150282203 no 1 0.1825635636652645 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-N9MR011VMC-U OHRF7YEV Skin Skin Cutaneous Melanoma RUFY1 SNV p.K225N 7 KLADYLNVL KLADYLKVL 9 5 179567533 A C HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.028 0.5 0.004 0.7603814 1.148 0.836973 -0.810930216 no 1 3.023272193793606 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-236NEQ2JD9-K OHRF7YEV Skin Skin Cutaneous Melanoma SMARCC2 SNV p.S624F 3 KVFEHVGSR KVSEHVGSR 9 12 56171900 G A HLA-A11:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.115 0.8 0.138 0.23685719 1.986 0.619811 -1.020258974 no 1 3.362729351790902 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-DA4VS975F2-D OHRF7YEV Skin Skin Cutaneous Melanoma MPV17 SNV p.R75G 4 VLDGFIPGT VLDRFIPGT 9 2 27312736 G C HLA-A02:01 CD8 multimer "PBMC_pre, PBMC_postVax, patient_TIL" peptide_pulsed_APC none 0.548 5 0.216 0.3754542 -1.006 0.059142 -0.840496893 no 1 3.887417648096396 PMID:31685621 Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens +NDDR-N6NTA1JDTE-W 352WTYXA Ovary Ovarian Cancer PPM1F SNV p.C259Y 7 FLAPLFLVLL FLAPLFCVLL 10 5 88203038 T G HLA-A24:02 CD8 ELISPOT "PBMC_postVax, patient_TIL" peptide_pulsed_APC none 8.36 3 1.457 0.027011096 0.736 -0.252377128 no 0 0.7803940963093237 PMID:32660279 Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites +NDDR-MCK2ZAJ8GQ-7 R7NU4BAT Brain Glioblastoma (GBM) WDR63 SNV p.T690M 8 FYNDIILMV FYNDIILTV 9 1 85124208 C T HLA-C06:02 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC none 0.042 34 0.001 0.93794346 0.026 0.518793793 no 0 PMID:30906654 Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma +NDDR-NWMYCN5E92-D X3AIF5LA Head & Neck Head and Neck Squamous Cell Carcinoma MAGOHB SNV p.G17A 8 RYYVGHKAKF RYYVGHKGKF 10 12 10613483 C G HLA-A24:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" "peptide_pulsed_APC, TMC_minigene" TMC 0.097 0.25 0.327 0.5310621 3.282 0.650931 -0.850239039 no 0 1.530218260762219 PMID:30906664 Identification of neoantigen-specific T cells and their targets: Implications for immunotherapy of head and neck squamous cell carcinoma +NDDR-S6DN480CYD-V XD6MQQ3M Ovary Ovarian Cancer SSC4D SNV p.D85Y 9 YGTGHILLY YGTGHILLD 9 7 76397626 C A HLA-B35:01 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 0.347 5 0.095 0.34794 2.496 0.067292 -5.180179441 yes 0 1.2413520857706586 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-VS85BXHK0E-W XD6MQQ3M Ovary Ovarian Cancer SSC4D SNV p.D85Y 9 YGTGHILLY YGTGHILLD 9 7 76397626 C A HLA-C12:03 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 0.117 18 0.008 0.0625905 2.496 0.067292 -5.774365724 yes 0 1.2413520857706586 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-HR56JF3PKD-V XD6MQQ3M Ovary Ovarian Cancer NAV1 SNV p.K349M 1 MAKAKAVAL KAKAKAVAL 9 HLA-B35:01 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 0.841 1.2 1.189 0.061466467 1.048 0.941944 -1.781601031 yes 0 0.4814022827632454 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-C5YZS7EBSD-V XD6MQQ3M Ovary Ovarian Cancer TRO SNV p.S598C 5 SVGACGFSY SVGASGFSY 9 X 54930991 C G HLA-B35:01 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 1.793 2.5 0.289 0.02986968 2.782 1.156591222 yes 0 1.6029319040696397 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-1V4ASC67M4-F XD6MQQ3M Ovary Ovarian Cancer CLEC10A SNV p.V143F 1 FPVHSEMLL VPVHSEMLL 9 17 7076078 C A HLA-B35:01 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 0.108 0.05 0.222 0.65602815 0.276 0.904387 -1.504077397 yes 0 -1.426237704423677 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-DHRA9GQ79C-U XD6MQQ3M Ovary Ovarian Cancer DDX60L SNV p.V257G 7 YVIFDEGHY YVIFDEVHY 9 4 168416796 A C HLA-A25:01 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 0.176 0.7 1.467 0.009464866 3.034 0.960788 0.40831006 no 0 0.3201958212661251 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-4JRXXBJTP9-K XD6MQQ3M Ovary Ovarian Cancer DDX60L SNV p.V257G 7 YVIFDEGHY YVIFDEVHY 9 4 168416796 A C HLA-A26:03 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 0.207 2.5 0.243 0.002461469 3.034 0.960788 0.659889959 no 0 0.3201958212661251 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-1NET55E0BS-9 XD6MQQ3M Ovary Ovarian Cancer OR51B4 SNV p.K183N 1 NLACADITF KLACADITF 9 11 5301398 T G HLA-B35:01 CD8 "4-1BB, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells" none 1.629 5.5 0.174 0.05186329 2.808 0.467745 -0.909515221 yes 0 -9.965784284662089 PMID:31069153 Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer +NDDR-C2M6EQ7T1C-U 3N22S6UG Pleura/Peritoneum (Mesothelium) Mesothelioma ROBO3 SNV p.P640H 3 SEHSPVSEPV SEPSPVSEPV 10 11 124874204 C A HLA-B49:01 CD8 "ELISPOT, multimer" "patient_TIL, TCR_clone" "peptide_pulsed_APC, TMC_minigene" TMC 0.123 0.4 1.985 0.000896022 0.454 0.978091 -1.310308454 no 0 1.7775775222037775 PMID:32002298 Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma +NDDR-K2DC19WSYP-6 XR365KHL Colon/Rectum Colorectal Adenocarcinoma AP2S1 SNV p.N86K 8 AYLEAIHKF AYLEAIHNF 9 19 46839474 G C HLA-A24:02 CD8 "ELISPOT, 4-1BB, multimer" "PBMC_pre, TCR_clone" "peptide_pulsed_APC, TMC_minigene" TMC 0.001 0.01 0.004 0.6267046 2.988 0.9139 0 no 1 5.890231347157432 PMID:33537174 Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions +NDDR-W656ADT8F2-D E2RCTTBH Colon/Rectum Colorectal Adenocarcinoma RAD21 SNV p.D116E 8 TLPEEFHEF TLPEEFHDF 9 20 1231599 T G HLA-A24:02 CD8 "ELISPOT, 4-1BB, multimer" "PBMC_pre, TCR_clone" "peptide_pulsed_APC, TMC_minigene" TMC 0.071 1.3 0.099 0.3135603 2.482 0.97333 -1.126391853 no 1 5.328211178598163 Other Tumor Driver PMID:33537174 Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions +NDDR-R26MH0CSKN-4 CNMRPXNS Skin Skin Cutaneous Melanoma CTNNB1 SNV p.S37F 9 SYLDSGIHF SYLDSGIHS 9 3 41224622 C T HLA-A24:02 CD8 51Cr "patient_TIL, TCR_clone" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.005 0.15 0.019 0.42225286 2.788 0.297074 -6.658524393 no 1 6.145806838558247 Tumor Driver PMID:8642260 A mutated beta-catenin gene encodes a Melanoma-specific antigen recognized by tumor infiltrating lymphocytes +NDDR-37B57SH6R0-B TUR5WXAA Brainstem Diffuse Intrinsic Pontine Glioma (DIPG) H3.3 SNV p.K27M 2 RMSAPSTGGV RKSAPSTGGV 10 HLA-A02:01 CD8 "ELISPOT, multimer" "PBMC_pre, TCR_clone" "peptide_pulsed_APC, TMC_minigene" endogenous(HLA-block) 3.181 2.5 4.599 0.1890224 0.638 -1.803479269 no 1 PMID:29203539 Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy +NDDR-45BGP1PWVE-W TSCSRBJX Lung Non-Small Cell Lung Cancer (NSCLC) HERC1 SNV p.P3278S 5 ASNASSAAK ASNAPSAAK 9 15 63656126 G A HLA-A11:01 CD8 multimer PBMC_pre NA none 0.063 0.2 0.202 0.016285526 0.628 0.757075 1.435084525 no 1 1.661703880118977 PMID:25765070 Mutational landscape determines sensitivity to PD-1 blockade in Non-Small Cell Lung Cancer +NDDR-ZZCXMGS11K-1 I7RVCSQA Skin Skin Cutaneous Melanoma TKT SNV p.R438W 4 AMFWSVPTV AMFRSVPTV 9 HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.048 0.06 0.049 0.6563868 0.914 0.613104473 no 1 5.450839799211661 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-EG72WSWBJ2-D I7RVCSQA Skin Skin Cutaneous Melanoma TMEM48 SNV p.F169L 9 CLNEYHLFL CLNEYHLFF 9 1 53825887 A G HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.471 0.7 0.02 0.63726187 0.71 -2.357925389 no 1 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-XS0VMV497T-A I7RVCSQA Skin Skin Cutaneous Melanoma CDKN2A SNV p.E153K 1 KMIGNHLWV EMIGNHLWV 9 9 21970902 C T HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.367 1.2 0.251 0.48655686 0.722 -2.239897718 no 1 1.258458621457592 Tumor Driver PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-VZY3AW8E59-K OHQJPMZB Skin Skin Cutaneous Melanoma MRPS5 SNV p.P59L 2 HLYASLSRA HPYASLSRA 9 HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.473 0.7 1.265 0.37619278 -0.25 0.772974 -3.771034095 no 0 2.6318840895149616 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-K689FMSYGB-T OHQJPMZB Skin Skin Cutaneous Melanoma EXOC8 SNV p.Q656P 7 IILVAVPHV IILVAVQHV 9 1 231335779 T G HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.269 0.8 0.135 0.51179826 0.442 0.914216 -0.695004191 no 1 2.0087179035446807 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-R0G5X7EEK3-E OHQJPMZB Skin Skin Cutaneous Melanoma PABPC1 SNV p.R520Q 5 MLGEQLFPL MLGERLFPL 9 13 25097877 G A HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.155 0.3 0.259 0.3916106 0.658 0.885752 -0.331853291 no 1 7.21061634113286 Other Tumor Driver PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-SNZZ9WV27P-6 LE64IB2Z Skin Skin Cutaneous Melanoma SEC24A SNV p.P469L 5 FLYNLLTRV FLYNPLTRV 9 5 134682397 C T HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.011 0.02 0.005 0.8063054 0.436 0.97348 0.78845736 no 1 2.349832322010078 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-Q70W8H7WCX-E LE64IB2Z Skin Skin Cutaneous Melanoma AKAP13 SNV p.Q285K 8 KLMNIQQKL KLMNIQQQL 9 15 85575321 C A HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.018 0.5 0.087 0.3996232 1.244 0.955397 0.587786665 no 1 2.2593611179809745 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-66X9B58J2S-9 LE64IB2Z Skin Skin Cutaneous Melanoma OR8B3 SNV p.T190I 5 QLSCISTYV QLSCTSTYV 9 11 124396783 G A HLA-A02:01 CD8 "ELISPOT, ICS" PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.805 0.7 0.037 0.5697854 0.166 0.819139 -0.695008801 no 1 -9.965784284662089 PMID:25837513 A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells +NDDR-8SEE5W52XN-4 ASV5ARII Colon/Rectum Colorectal Adenocarcinoma CASP8 SNV p.F67V 4 ELLVRINRL ELLFRINRL 9 HLA-B08:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.018 2.5 0.024 0.31329224 0.614 0.934579 -0.635988767 yes 0 2.5103543088155917 Other Tumor Driver PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-XMJTSB7ZM1-C ABT5UFIF Colon/Rectum Colorectal Adenocarcinoma KRAS SNV p.G12D 3 GADGVGKSAL GAGGVGKSAL 10 HLA-C05:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.409 17 0.627 0.15130626 0.568 0.438231 -3.503668642 no 1 2.9917856922921353 Tumor Driver PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-GGQCET69F7-I ABT5UFIF Colon/Rectum Colorectal Adenocarcinoma KRAS SNV p.G12D 3 GADGVGKSAL GAGGVGKSAL 10 HLA-C08:02 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.171 15 0.17 0.18107818 0.568 0.438231 -4.094344562 no 1 2.9917856922921353 Tumor Driver PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-1PCSWDWSSK-1 FFRFFTSB Colon/Rectum Colorectal Adenocarcinoma SKIV2L SNV p.R653H 6 EMLFSHGLVK EMLFSRGLVK 10 HLA-A03:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.672 3 0.997 0.08092839 0.234 -0.221952366 no 0 3.394047590132866 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-S8SEJXG8AF-X FFRFFTSB Colon/Rectum Colorectal Adenocarcinoma SKIV2L SNV p.R653H 5 MLFSHGLVK MLFSRGLVK 9 HLA-A03:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.011 0.12 0.031 0.18879895 0.718 -0.435318071 no 0 3.394047590132866 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-B97ZRMVPRV-C Q5EFISOX Colon/Rectum Colorectal Adenocarcinoma PHLPP1 SNV p.G566E 4 ILCETCLIV ILCGTCLIV 9 18 62830155 G A HLA-A02:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 1.593 0.25 0.118 0.5297906 0.308 0.944836 -0.571472401 no 1 1.3514587222137173 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-QTM9DE22BE-W Q5EFISOX Colon/Rectum Colorectal Adenocarcinoma API5 SNV p.R243Q 6 LLQCTQQAV LLQCTRQAV 9 HLA-A02:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 1.596 1.2 0.781 0.29171476 0.304 0.168038 -0.839209383 no 0 4.559004648541702 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-HNTCR16H6A-S Q5EFISOX Colon/Rectum Colorectal Adenocarcinoma API5 SNV p.R243Q 7 RLLQCTQQAV RLLQCTRQAV 10 HLA-A02:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 1.056 0.15 1.857 0.121157765 0.572 0.168038 -0.691725716 no 0 4.559004648541702 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-ABZZYTEMDY-F CUZXO5J4 Pancreas Pancreatic Adenocarcinoma (PDAC) ZFYVE27 SNV p.R6H 2 EHEGSGPEL EREGSGPEL 9 HLA-B38:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.012 13 0.077 0.080678545 0.242 0.965456 -2.746201967 no 0 3.5900749987919154 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-SJKB4RNY1P-6 CUZXO5J4 Pancreas Pancreatic Adenocarcinoma (PDAC) ZFYVE27 SNV p.R6H 3 SEHEGSGPEL SEREGSGPEL 10 HLA-B38:01 CD8 "ELISPOT, 4-1BB" patient_TIL "peptide_pulsed_APC, TMC_minigene" TMC 0.076 4 8.662 0.00375491 1.094 0.965456 -2.584990108 no 0 3.5900749987919154 PMID:26516200 Immunogenicity of somatic mutations in human Colorectal Cancers +NDDR-58EN4WZN3K-1 DRAI56NY Lung Non-Small Cell Lung Cancer (NSCLC) MTFR2 SNV p.D283Y 6 FAFQEYDSF FAFQEDDSF 9 6 136233393 C A HLA-B35:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.071 1.1 0.055 0.5672879 2.574 0.505318 -0.106767975 yes 0 1.1642391077872483 PMID:26940869 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade +NDDR-8SSFF6Q7MD-V JHK3ND2A Lung Non-Small Cell Lung Cancer (NSCLC) CHTF18 SNV p.L351V 5 LLLDIVAPK LLLDILAPK 9 16 793207 C G HLA-A11:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.552 0.4 0.188 0.21507737 0.554 0.930052 -0.09333194 no 0 1.81913615064278 PMID:26940869 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade +NDDR-DZ1AEM5MX5-G JHK3ND2A Lung Non-Small Cell Lung Cancer (NSCLC) MYADM SNV p.R30W 9 SPMIVGSPW SPMIVGSPR 9 19 53873617 C T HLA-B07:02 CD8 multimer patient_TIL peptide_pulsed_APC none 0.316 0.6 0.719 0.5504699 0.498 0.960977 -1.708767621 no 0 4.112007514695531 PMID:26940869 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade +NDDR-HK59W4KGF1-C WHG2YFVM Skin Skin Cutaneous Melanoma GCN1L1 SNV p.L2330P 6 ALLETPSLL ALLETLSLL 9 12 120136521 A G HLA-A02:01 CD8 "multimer, ELISPOT" PBMC_pre TMC_minigene none 0.045 1.3 0.048 0.54578054 1.256 0.223143551 no 0 PMID:27198675 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires +NDDR-B31HC61QZZ-G WHG2YFVM Skin Skin Cutaneous Melanoma GCN1L1 SNV p.L2330P 6 ALLETPSLLL ALLETLSLLL 10 12 120136521 A G HLA-A02:01 CD8 "multimer, ELISPOT" PBMC_pre TMC_minigene none 0.154 1.3 0.143 0.30405095 1.256 -0.464305608 no 1 PMID:27198675 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires +NDDR-5EN6GMHBB6-H WHG2YFVM Skin Skin Cutaneous Melanoma CDK4 SNV p.R71L 2 ALDPHSGHFV ARDPHSGHFV 10 12 57751647 C A HLA-A02:01 CD8 "multimer, ELISPOT" PBMC_pre TMC_minigene none 0.085 1.2 0.065 0.4697877 0.228 0.668099 -4.919637372 no 1 4.89146952891671 Tumor Driver PMID:27198675 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires +NDDR-CYCDC4BR97-I WHG2YFVM Skin Skin Cutaneous Melanoma DNAH17 SNV p.H8302Y 9 VLFEDAVAY VLFEDAVAH 9 17 78475445 G A HLA-B15:01 CD8 "multimer, ELISPOT" PBMC_pre TMC_minigene none 0.019 0.07 0.022 0.2762412 3.2 0.131474 -4.076644985 no 0 -3.134162571958985 PMID:27198675 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires +NDDR-NTP91MW8Y6-H 7TRJS5PW Skin Skin Cutaneous Melanoma BRWD1 SNV p.R925W 8 KPKKENLWRM KPKKENLRRM 10 21 39232492 G A HLA-B07:02 CD8 "multimer, ELISPOT" PBMC_pre TMC_minigene none 0.459 0.2 1.201 0.37370968 -0.122 0.278546 0.105602617 no 0 1.1671330737904817 PMID:27198675 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires +NDDR-YFVCRQNZKS-9 7TRJS5PW Skin Skin Cutaneous Melanoma PARG SNV p.Y427N 7 ELMRDINSM ELMRDIYSM 9 10 49820207 A T HLA-B35:01 CD8 "multimer, ELISPOT" PBMC_pre TMC_minigene none 1.031 9.5 1.963 0.25263783 0.058 0.880625 0.166348928 yes 0 1.9625489996545604 PMID:27198675 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires +NDDR-5M206ARJMA-S G3MJINSO Cervix Cervical Carcinoma (HPV+) ALDH1A1 SNV p.N150I 6 IPIDGIFFTY IPIDGNFFTY 10 HLA-B35:01 CD8 CD107a patient_TIL "TMC_minigene, peptide_pulsed_APC" none 0.017 0.03 0.004 0.67217404 2.456 0.977859 0.060624622 yes 0 2.8478282313603214 PMID:28408606 Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer +NDDR-SY7527TDDR-8 G3MJINSO Cervix Cervical Carcinoma (HPV+) METTL17 SNV p.E279K 3 RTKVVQTLW RTEVVQTLW 9 14 20994860 G A HLA-A32:01 CD8 CD107a patient_TIL "TMC_minigene, peptide_pulsed_APC" none 0.015 0.01 0.037 0.22831242 1.128 0.940368 -1.866660777 no 0 2.8572511252854564 PMID:28408606 Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer +NDDR-TPTWEFDEXD-V G3MJINSO Cervix Cervical Carcinoma (HPV+) SETDB1 SNV p.E21D 5 VESEDIAEL VESEEIAEL 9 1 150927777 G C HLA-B40:01 CD8 CD107a patient_TIL "TMC_minigene, peptide_pulsed_APC" none 0.023 0.3 0.023 0.26135123 1.012 0.963706 0.245122458 no 0 1.9320599329227528 Other Tumor Driver PMID:28408606 Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer +NDDR-XJPM5HK7FN-4 EXWFDAWT Blood/Bone marrow Leukemia PLCD3 SNV p.D314H 5 LMTLHGFMMY LMTLDGFMMY 10 17 45118466 C G HLA-A30:02 CD8 multimer patient_TIL peptide_pulsed_APC none 1.197 2.5 0.376 0.9905976 3.016 0.978922 0.783124903 no 0 -0.0357862220530606 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-DCNJ84M5D6-H EXWFDAWT Blood/Bone marrow Leukemia PLCD3 SNV p.D314H 4 MTLHGFMMY MTLDGFMMY 9 17 45118466 C G HLA-A30:01 CD8 multimer patient_TIL peptide_pulsed_APC none 1.854 14 0.206 0.8741233 3.016 0.978922 0.123259167 no 0 -0.0357862220530606 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-CYHGXP9VS1-C EXWFDAWT Blood/Bone marrow Leukemia PLCD3 SNV p.D314H 4 MTLHGFMMY MTLDGFMMY 9 17 45118466 C G HLA-A30:02 CD8 multimer patient_TIL peptide_pulsed_APC none 0.124 1.1 0.061 0.9972703 3.016 0.978922 1.131402111 no 0 -0.0357862220530606 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-3C01ZQFFQT-A KX6Z6VLS Blood/Bone marrow Leukemia MCTP1 SNV p.R783H 5 IRMKHCVMV IRMKRCVMV 9 5 94868421 C T HLA-C07:02 CD8 multimer patient_TIL peptide_pulsed_APC none 1.191 13 0.984 0.25567743 0.732 0.406404 -0.509313146 no 0 2.345595080031881 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-BPHQDRGQM2-D VTEIFCU7 Blood/Bone marrow Leukemia SPATA5 SNV p.S812C 6 KLQFHCMPV KLQFHSMPV 9 4 123256110 C G HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 1.353 0.07 0.517 0.32274988 0.41 1.121034753 no 0 1.2577951343833695 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-7GF9E27P3J-0 D3NMWBFW Blood/Bone marrow Leukemia GPR139 SNV p.A298T 2 ATTLKAFFK AATLKAFFK 9 16 20031905 C T HLA-A03:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.246 0.25 0.068 0.4999201 0.684 0.574528 -1.437790887 no 0 -9.965784284662089 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-ST51E6YP0B-T D3NMWBFW Blood/Bone marrow Leukemia GPR139 SNV p.A298T 6 RTMAATTLK RTMAAATLK 9 16 20031905 C T HLA-A03:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.014 0.01 0.014 0.6425206 0.842 0.502898 -0.405465108 no 0 -9.965784284662089 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-Q1K8PG6J2Z-G G33NW4LL Blood/Bone marrow Leukemia ATP13A4 SNV p.L109F 3 HPFMTDEEY HPLMTDEEY 9 3 193502549 G A HLA-B35:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.004 0.03 0.004 0.80949837 2.478 0.619438 -0.693147181 yes 0 -2.571750389294305 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-Y9RZGDTEDJ-0 G33NW4LL Blood/Bone marrow Leukemia SLC6A7 SNV p.R62C 6 LGNVWCFPY LGNVWRFPY 9 X 116437922_116437924 AGA TGT HLA-B35:01 CD8 multimer patient_TIL peptide_pulsed_APC none 6.302 2 1.455 0.338483 2.58 0.924153 0.427444015 yes 0 -6.9839316313723465 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-7VCA888E87-I G33NW4LL Blood/Bone marrow Leukemia ASXL3 SNV p.E1718K 5 SPMEKAISL SPMEEAISL 9 18 33745000 G A HLA-B35:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.077 0.5 0.146 0.4495259 0.568 0.967474 0.582605306 yes 0 -8.20024953829911 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-NKSNK60CB6-H G33NW4LL Blood/Bone marrow Leukemia DTX3L SNV p.D141H 3 TAHLNCNLF TADLNCNLF 9 3 122568510 G C HLA-B35:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.678 2.5 0.606 0.30075976 2.64 0.941967 -0.188936796 yes 0 4.171647192192975 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-KS17EZFBT2-D M2ABZXMV Blood/Bone marrow Leukemia CD101 SNV p.S889F 9 HLHCYRSSF HLHCYRSSS 9 1 117025746 C T HLA-B15:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.575 1 0.19 0.24389473 2.506 0.028623 -3.756944359 no 0 0.4464679860973253 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-VF8W5J2PV2-D M2ABZXMV Blood/Bone marrow Leukemia TMEM104 SNV p.V281I 6 LFGVCIYSF LFGVCVYSF 9 17 74836037 G A HLA-A24:02 CD8 multimer patient_TIL peptide_pulsed_APC none 0.907 0.5 0.042 0.17712702 2.37 0.806016 0.00331309 no 0 3.3255878943110875 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-B42P9N7VWT-A M2ABZXMV Blood/Bone marrow Leukemia FAM157B SNV p.L156F 2 RFLHDLHLL RLLHDLHLL 9 HLA-A24:02 CD8 multimer patient_TIL peptide_pulsed_APC none 0.146 0.6 0.017 0.2591804 1.32 0.875295 -2.290179696 no 0 -3.255666652618641 PMID:31243155 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses +NDDR-KJVBD2731B-T 5VPZ7ZNO Kidney Collecting Duct Carcinoma SLC27A3 SNV p.Y704C 8 FLQEVNVCGV FLQEVNVYGV 10 HLA-A02:03 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC none 0.313 0.07 0.482 0.3850943 -0.002 0.643552 0.269739639 no 0 PMID:32439798 Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report +NDDR-BYMHBVR7MN-4 5VPZ7ZNO Kidney Collecting Duct Carcinoma KRAS SNV p.G12D 8 KLVVVGADGV KLVVVGAGGV 10 12 25245350 C T HLA-A02:03 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC none 3.298 1.7 8.407 0.1703924 0.63 0.35561 0.029852963 no 0 Other Tumor Driver PMID:32439798 Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report +NDDR-PHW5551Z24-F 5VPZ7ZNO Kidney Collecting Duct Carcinoma DHX29 SNV p.V1219E 5 LLKAELVAGL LLKAVLVAGL 10 5 55262802 A T HLA-A02:03 CD8 ELISPOT PBMC_postVax peptide_pulsed_APC none 0.853 1.7 0.961 0.30452138 1.004 0.247439 -1.000993859 no 0 PMID:32439798 Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report +NDDR-G1RSZ7MRBS-9 GTFUJIR3 Skin Skin Cutaneous Melanoma WDR1 SNV p.N544K 10 DSFAGKGHTK DSFAGKGHTN 10 4 10083120 G C HLA-A68:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.178 2 0.14 0.17912829 0.454 0.073674 -5.058176239 no 0 5.888243884763167 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-G5EC8HGKHQ-7 GTFUJIR3 Skin Skin Cutaneous Melanoma VARS SNV p.T1062M 7 EVADEAMGAL EVADEATGAL 10 HLA-A25:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.174 0.08 0.293 0.26052454 0.73 -0.393904286 no 0 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-ZZYSGAHKME-W GTFUJIR3 Skin Skin Cutaneous Melanoma MYLK SNV p.G691V 7 EVFPEDTVTY EVFPEDTGTY 10 3 123708766 C A HLA-A25:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.004 0.25 0.015 0.2766524 2.89 0.973908 -0.223143551 no 0 0.6236768736843954 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-VHY0P4RGXB-T GTFUJIR3 Skin Skin Cutaneous Melanoma RBM12 SNV p.S424L 1 LPHEAGFCV SPHEAGFCV 9 20 35654052 G A HLA-B51:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.095 0.03 0.051 0.4229979 -0.154 0.969313 -1.105605324 yes 0 3.649667109365193 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-9KFN92EGN8-J GTFUJIR3 Skin Skin Cutaneous Melanoma LRP3 SNV p.T722S 9 LTAARPSQSVL LTAARPSQTVL 11 19 33207160 C G HLA-A25:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 9.597 3.5 14.249 0.000551931 1.068 0.964317 -0.016636912 no 0 1.5874537988404145 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-C892E3W17C-U YJCPSI7I Skin Skin Cutaneous Melanoma ENTPD4 SNV p.P85L 7 ATDTNNLNVNY ATDTNNPNVNY 11 8 23447838 G A HLA-A01:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.022 0.01 0.21 0.6612412 2.864 0.96242 -0.405465108 no 0 3.1196292036020346 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-Q8ETT3PMN2-D YJCPSI7I Skin Skin Cutaneous Melanoma TTC37 SNV p.A692V 6 YLDGKVVDY YLDGKAVDY 9 5 95520755 G A HLA-A01:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.031 0.9 0.011 0.6774577 2.426 -0.031748698 no 0 3.00543587954074 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-8FAN95FX4H-Z YJCPSI7I Skin Skin Cutaneous Melanoma MAB21L1 SNV p.V321M 9 LRIRDRYVM LRIRDRYVV 9 13 35475637 C T HLA-B08:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 5.02 4 6.534 0.023552766 0.808 0.874276 -0.81772426 yes 0 -4.553066360401127 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-CFTCW1YZ6Y-F MP5A4MPY Skin Skin Cutaneous Melanoma RAD51AP1-002 SNV p.S241F 4 KVKFPVEKK KVKSPVEKK 9 12 4553097 C T HLA-A03:01 CD8 multimer patient_TIL "tumor_cells, peptide_pulsed_APC" none 0.018 0.4 0.014 0.54931486 0.738 0.810930216 no 0 PMID:32753545 Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up +NDDR-J7YKRKVGDN-4 VQQXFXNM Ovary Ovarian Cancer HSDL1 SNV p.L25V 6 CYMEAVALV CYMEALALV 9 16 84131249 G C HLA-C14:03 CD8 ELISPOT "patient_TIL, PBMC_pre" peptide_pulsed_APC none 1.163 12 0.147 0.042784397 0.54 0.365067 -0.234939568 no 0 1.882956006881632 PMID:24323902 Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer +NDDR-YP77ANFST5-G ZPRTYQED Skin Skin Cutaneous Melanoma COL181A SNV p.S126F 8 VLLGVKLFGV VLLGVKLSGV 10 21 45468512 C T HLA-A02:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.491 0.4 0.11 0.52074325 0.402 -0.154441589 no 1 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-FKNNSG8XXX-E U4R2OSJM Skin Skin Cutaneous Melanoma RECQL5 SNV p.P816L 11 GEEDGAGGHSL GEEDGAGGHSP 11 17 75628976 G A HLA-B44:02 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.826 6 1.532 0.02044143 0.578 0.094773 -2.035037929 no 0 2.0929851697611346 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-9EBFKS8BE0-B U4R2OSJM Skin Skin Cutaneous Melanoma UGGT2 SNV p.P882L 2 GLLDEDFYA GPLDEDFYA 9 13 95895294 G A HLA-A02:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.13 2 0.04 0.6822859 -0.602 0.680007 -5.303381446 no 0 1.7479234185758776 Other Tumor Driver PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-KDS5AYDE9G-Y U4R2OSJM Skin Skin Cutaneous Melanoma FBXO21 SNV p.S250Y 2 SYMIMEIEL SSMIMEIEL 9 12 117174332 G T HLA-C14:02 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.094 25 0.009 0.7339669 1.302 0.654397 -4.319755046 yes 0 2.5870995364740947 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-W8302P07KB-T U4R2OSJM Skin Skin Cutaneous Melanoma XPNPEP1 SNV p.S639T 10 WLIRETQPITK WLIRETQPISK 11 10 109865198 A T HLA-A03:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 1.963 2.5 3.516 0.14389448 0.448 0.973393 0.014366589 no 0 3.383917756138871 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-8HGA5WFX6S-9 PPKWDFGG Skin Skin Cutaneous Melanoma TFDP2 SNV p.A270T 5 GQFLTPNSH GQFLAPNSH 9 3 141952638 C T HLA-B15:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.369 4 0.388 0.44904605 -0.202 0.806689 -0.057910916 no 0 1.7325407960953627 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-00P571BG65-G UCE5HKKE Skin Skin Cutaneous Melanoma PHKA1 SNV p.P34L 10 HQNPVTGLLL HQNPVTGLLP 10 X 72712915 G A HLA-B38:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.451 0.3 0.227 0.6704648 0.89 0.034755 -2.919148102 no 0 -0.009890635455803 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-M571B9D7AN-4 UCE5HKKE Skin Skin Cutaneous Melanoma KIAA1967 SNV p.H227Y 10 RHDLPPYRVYL RHDLPPYRVHL 11 8 22613111 C T HLA-B38:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.125 6 0.595 0.0226748 0.776 -0.031498667 no 0 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-GBFX050B7K-1 UCE5HKKE Skin Skin Cutaneous Melanoma KIAA1279 SNV p.P246S 3 YHSIEWAI YHPIEWAI 8 10 69005862 C T HLA-B38:01 CD8 "ELISPOT, 4-1BB" patient_TIL TMC_minigene none 0.184 0.5 0.142 0.4799058 0.332 -0.240385358 no 0 PMID:27827318 Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression +NDDR-7052R2DHND-V OP4YBPHD Ovary Ovarian Cancer BRAP SNV p.R543C 3 QLCDVMFYL QLRDVMFYL 9 12 111644378 G A HLA-A02:01 CD8 "ELISPOT, 4-1BB, multimer" "TCR_clone, healthy_donor_PBMC" peptide_pulsed_APC none 0.12 0.4 0.004 0.5973775 0.832 0.972631 -0.416514944 no 0 2.579687030220663 PMID:29720506 Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer +NDDR-5S6XME4F5F-X BCIKPFC2 Ovary Ovarian Cancer RFC5 SNV p.K160N 4 YLSNIIPAL YLSKIIPAL 9 12 118024909 G C HLA-A02:01 CD8 "ELISPOT, 4-1BB, multimer" "TCR_clone, healthy_donor_PBMC" peptide_pulsed_APC none 0.008 0.03 0.005 0.6683105 0.8 0.966923 0 no 0 2.8318772411916733 PMID:29720506 Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer +NDDR-3ZY9QZNQXN-4 BCIKPFC2 Ovary Ovarian Cancer GINS1 SNV p.I87V 9 YLYDRLLRV YLYDRLLRI 9 20 25418124 A G HLA-A02:01 CD8 "ELISPOT, 4-1BB, multimer" "TCR_clone, healthy_donor_PBMC" peptide_pulsed_APC none 0.002 0.02 0.007 0.7756753 0.542 0.953791 -1.386294361 no 0 2.389126226924704 PMID:29720506 Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer +NDDR-FZTSJMS64Q-7 FDCHYTN3 Bone marrow Multiple Myeloma EVI2B SNV p.G327A 9 DSADGSTVATA DSADGSTVGTA 11 17 31304630 C G HLA-A68:02 CD8 ICS PBMC_pre peptide_pulsed_APC none 1.352 10 1.397 0.4630514 -0.736 0.548426 -0.861565832 no 0 PMID:31857430 Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma +NDDR-91HRG4BTBH-Z JAR22V53 Bone marrow Multiple Myeloma PRKDC SNV p.Q823E 9 VSALSRAAEK VSALSRAAQK 10 8 47918336 G C HLA-A03:01 CD8 ICS PBMC_pre peptide_pulsed_APC none 1.679 1.2 3.312 0.14334771 0.636 0.345868 0.412937867 no 0 PMID:31857430 Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma +NDDR-QCH9V1GARW-D 3PCSYXUC Bone marrow Multiple Myeloma S100A9 SNV p.T18N 7 IETIINNFHQY IETIINTFHQY 11 1 153358336 C A HLA-B44:03 CD8 ICS PBMC_pre peptide_pulsed_APC none 0.353 0.09 0.822 0.5827813 2.842 0.978122 0.213978877 yes 0 PMID:31857430 Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma +NDDR-AZ9A9GK0V8-J V4S75ZZC Lung Non-Small Cell Lung Cancer (NSCLC) PGAP1 SNV p.Y903F 8 AFGSAHLFR AFGSAHLYR 9 2 196841295 T A HLA-A31:01 CD8 "ELISPOT, ICS" PBMC_pre peptide_pulsed_APC endogenous(HLA-block) 0.247 3.5 0.164 0.033942964 1.532 0.213232 0.236388778 no 0 0.6982183795788264 PMID:28031159 Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer +NDDR-SQGGCG6BKT-A V4S75ZZC Lung Non-Small Cell Lung Cancer (NSCLC) HELB SNV p.P987S 6 SASPLSVV SASPLPVV 8 12 66331442 C T HLA-C15:02 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_TIL" peptide_pulsed_APC TMC 1.053 1.6 6.152 0.007815836 0.44 0.206922 0.586078723 no 0 -0.76 PMID:28031159 Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer +NDDR-3WA072BDQH-Z V4S75ZZC Lung Non-Small Cell Lung Cancer (NSCLC) PGAP1 SNV p.Y903F 10 VIAFGSAHLFR VIAFGSAHLYR 11 2 196841295 T A HLA-A31:01 CD8 "ELISPOT, ICS" PBMC_pre peptide_pulsed_APC endogenous(HLA-block) 0.998 1 0.692 0.017975297 1.686 0.213232 0.245178126 no 0 0.6982183795788264 PMID:28031159 Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer +NDDR-RJJJVF07Q8-J V4S75ZZC Lung Non-Small Cell Lung Cancer (NSCLC) SLC26A7 SNV p.R117Q 8 ISANAVEQIV ISANAVERIV 10 8 91295576 G A HLA-C15:02 CD8 "ELISPOT, ICS" PBMC_pre peptide_pulsed_APC endogenous(HLA-block) 4.912 2.5 1.839 0.11867749 0.41 0.084058 0.125651862 no 0 -4.40 PMID:28031159 Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. +NDDR-HRWDRJBJW0-B V4S75ZZC Lung Non-Small Cell Lung Cancer (NSCLC) HELB SNV p.P987S 9 STPSASPLSV STPSASPLPV 10 12 66331442 C T HLA-C15:02 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_TIL" peptide_pulsed_APC TMC 1.249 19 8.457 0.013158833 0.376 0.916327 -1.072931732 no 0 -0.76 PMID:28031159 Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. +NDDR-VNE4XNP8NJ-0 DXUG6JS4 Skin Skin Cutaneous Melanoma MED15 SNV p.P747S 4 DANSFLQSV DANPFLQSV 9 22 20586576 C T HLA-B51:01 CD8 "multimer, ELISPOT" patient_TIL "tumor_cells, peptide_pulsed_APC" MS 0.01 4 0.001 0.8711061 -0.126 0.965305 0.510825624 yes 0 4.421583505080367 PMID:30209080 Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma +NDDR-VFJ1HW8KKQ-7 DXUG6JS4 Skin Skin Cutaneous Melanoma NCAPH2 SNV p.S181Y 3 GVYPMPGTQK GVSPMPGTQK 10 HLA-A03:01 CD8 "multimer, ELISPOT" patient_TIL "tumor_cells, peptide_pulsed_APC" MS 0.005 0.15 0.016 0.6496652 0.854 0.94295 -2.00148 no 0 4.046185207556744 PMID:30209080 Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma +NDDR-8546NTA30S-9 VXLPQZMT Colon/Rectum Colorectal Adenocarcinoma MYO5B SNV p.K1410Q 7 NENLDLQEL NENLDLKEL 9 18 49849654 T G HLA-B40:01 CD8 multimer PBMC_pre peptide_pulsed_APC none 0.128 0.8 0.074 0.08536049 1.02 0.761647 -0.410659925 no 0 3.432878849521966 PMID:38039963 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers +NDDR-4X6MSRCG9M-3 VXLPQZMT Colon/Rectum Colorectal Adenocarcinoma ARMC9 SNV p.L146F 4 TEFFPFYAL TEFLPFYAL 9 2 231216725 C T HLA-B40:01 CD8 multimer PBMC_pre peptide_pulsed_APC none 0.053 0.5 0.004 0.74692786 1.17 0.975608 0.232622295 no 0 0.19874557636851695 PMID:38039963 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers +NDDR-ZEXNA40QMF-X A4433WE5 Skin Skin Cutaneous Melanoma SEC22C SNV p.H248Y 9 AEHSLQVAY AEHSLQVAH 9 3 42555989 G A HLA-B44:03 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.003 0.03 0.035 0.65933895 3.264 0.069098 -4.857225081 yes 0 2.964352206962708 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-BJNX57J42T-A A4433WE5 Skin Skin Cutaneous Melanoma AFMID SNV p.A87V 2 EVLPFFLFF EALPFFLFF 9 17 78202703 C T HLA-A29:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.572 1.3 0.006 0.6574246 2.312 0.911089 -0.643876132 yes 0 2.3634910769146917 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-XRFB4NYHXS-9 A4433WE5 Skin Skin Cutaneous Melanoma PRDX3 SNV p.P44L 4 FFYLLDFTF FFYPLDFTF 9 10 119174460 G A HLA-A29:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.443 1.8 0.157 0.87589324 2.764 0.931843 2.355900152 yes 0 4.902441249653209 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-Y2Z4X3P1JM-3 A4433WE5 Skin Skin Cutaneous Melanoma GCN1 SNV p.P769L 5 IMQTLAGELY IMQTPAGELY 10 12 120161916 G A HLA-A29:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.447 0.9 0.765 0.95175177 2.946 0.93323 0.794290897 yes 0 4.221440070993674 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-6CX6JH2JPN-4 A4433WE5 Skin Skin Cutaneous Melanoma HELZ2 SNV p.D45N 3 QTNPVTLQY QTDPVTLQY 9 20 62198871 G A HLA-A29:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.002 0.04 0.015 0.96728057 2.622 0.978844 -1.504077397 yes 0 2.540976820076291 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-RVJSEHY3SB-T A4433WE5 Skin Skin Cutaneous Melanoma PLSCR4 SNV p.R247C 3 RVCGPCSTY RVRGPCSTY 9 3 146196679 G A HLA-A29:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.351 1.5 0.748 0.925121 3.282 0.978774 -0.331576266 yes 0 1.5328401626458188 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-JAZ60H7WTC-U A4433WE5 Skin Skin Cutaneous Melanoma TPX2 SNV p.H458Y 9 TEDEHFEFY TEDEHFEFH 9 20 31783880 C T HLA-B44:03 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.062 0.5 0.002 0.7403499 2.564 0.210275 -2.697239285 yes 0 4.681660661213192 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-RT21NV6BXT-A A4433WE5 Skin Skin Cutaneous Melanoma SRPX SNV p.P55L 2 TLWCSPIKV TPWCSPIKV 9 X 38174345 G A HLA-A02:01 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.082 1.6 0.068 0.5705981 0.636 0.964149 -5.024762673 no 1 5.953749044438666 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-FZSSX30FWZ-G A4433WE5 Skin Skin Cutaneous Melanoma CENPL SNV p.P79L 7 TLYSLTLLY TLYSLTPLY 9 1 173807451 G A HLA-A29:02 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.001 0.01 0.001 0.9842509 3.276 0.971861 -1.386294361 yes 0 1.234530764796478 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-S5M12PJKER-8 A4433WE5 Skin Skin Cutaneous Melanoma WDR46 SNV p.T300I 3 FLIYLDVSV FLTYLDVSV 9 6 33287207 G A HLA-A02:01 CD8 "ELISPOT, 4-1BB" "patient_TIL, TCR_clone" TMC_minigene endogenous(HLA-block) 0.123 0.17 0.124 0.5000206 0.2 0.152263 -0.198450939 no 1 5.306262756328292 PMID:27312342 Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens +NDDR-R36XZ74D2F-X JJRPX753 Breast Breast Cancer ROBO3 SNV p.A1287V 2 RVAGSMSSL RAAGSMSSL 9 11 124879850 C T HLA-B07:02 CD8 ELISPOT PBMC_pre "tumor_cells, peptide_pulsed_APC" endogenous(HLA-block) 0.26 0.6 0.117 0.07093977 1.328 0.967618 0.122602322 no 1 -1.2438306819752205 PMID:28619968 Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity +NDDR-AHM88B8PVS-9 JJRPX753 Breast Breast Cancer PALB2 SNV p.H198D 9 SPVTEIRTDL SPVTEIRTHL 10 16 23635954 G C HLA-B07:02 CD8 ELISPOT PBMC_pre "tumor_cells, peptide_pulsed_APC" endogenous(HLA-block) 0.154 0.9 0.354 0.13529685 0.594 0.972951 0.746493161 no 1 2.045914337083082 Other Tumor Driver PMID:28619968 Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity +NDDR-3ZZYVXS3EE-W QFNXKYKQ Breast Breast Cancer PTPRS SNV p.R1207W 7 RQLEVPWPYI RQLEVPRPYI 10 19 5220088 G A HLA-A02:01 CD8 ELISPOT PBMC_pre "tumor_cells, peptide_pulsed_APC" none 0.592 1.6 0.582 0.08275931 1.004 0.560228 -0.340325806 no 1 2.6617720334514887 PMID:28619968 Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity +NDDR-407E004WJN-4 PE5QXW4K Breast Breast Cancer ZDHHC16 SNV p.H288L 9 ALGALTVWL ALGALTVWH 9 10 97455698 A T HLA-A02:01 CD8 ELISPOT PBMC_pre "tumor_cells, peptide_pulsed_APC" none 0.574 3.5 0.206 0.55235475 0.894 0.038458 -3.570758818 no 1 3.8864525971067927 PMID:28619968 Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity +NDDR-KQ8T2M2TH4-F 6VPEE6FY Colon/Rectum Colorectal Adenocarcinoma TP53 SNV p.Y220C 4 VVPCEPPEV VVPYEPPEV 9 HLA-A02:01 CD8 "ELISPOT, 4-1BB, HLA-block" patient_TIL peptide_pulsed_APC endogenous(HLA-block) 0.751 9 1.073 0.3173151 0.454 0.687508 0.629941105 no 1 4.49708538278116 Tumor Driver PMID:30714987 Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers +NDDR-2RKK51DFKZ-G TE6XNJKV Colon/Rectum Colorectal Adenocarcinoma TP53 SNV p.R175H 8 HMTEWRHC HMTEWRHR 8 HLA-A02:01 CD8 "ELISPOT, 4-1BB, HLA-block" patient_TIL peptide_pulsed_APC endogenous(HLA-block) 30.273 6 38.64 0.29153964 -0.036 -0.287954555 no 0 4.49708538278116 Tumor Driver PMID:30714987 Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers +NDDR-Y5YMFQGM88-J RXNERV56 Colon/Rectum Colorectal Adenocarcinoma TP53 SNV p.R175H 8 HMTEWRHC HMTEWRHR 8 HLA-A02:01 CD8 "ELISPOT, 4-1BB, HLA-block" patient_TIL peptide_pulsed_APC endogenous(HLA-block) 30.273 6 38.64 0.29153964 -0.036 -0.287954555 no 0 4.49708538278116 Tumor Driver PMID:30714987 Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers +NDDR-XZCQ5QV77G-Y I4ZR7YUA Colon/Rectum Colorectal Adenocarcinoma TP53 SNV p.R248W 9 SSCMGGMNWR SSCMGGMNRR 10 17 7674221 G A HLA-A68:01 CD8 "ELISPOT, 4-1BB, HLA-block" patient_TIL peptide_pulsed_APC endogenous(HLA-block) 0.995 1.6 1.964 0.19980375 1.654 0.066026 0.526015789 no 0 4.49708538278116 Tumor Driver PMID:30714987 Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers +NDDR-YVEY0T9SF2-D JXPQ4HGM Stomach Gastric Adenocarcinoma OR10H1 SNV p.E297V 2 KVLKVAMKK KELKVAMKK 9 HLA-A03:01 CD8 4-1BB PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.007 0.02 0.013 0.592961 0.778 0.92175 -5.894009211 no 0 -6.1177873781071375 PMID:33016924 mRNA vaccine induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer +NDDR-0NVE3V4N95-G JXPQ4HGM Stomach Gastric Adenocarcinoma COL6A3 SNV p.G346W 3 TAWQSEDSY TAGQSEDSY 9 HLA-B35:01 CD8 4-1BB PBMC_postVax peptide_pulsed_APC endogenous(HLA-block) 0.04 2 0.082 0.21853267 3.314 0.428246 -1.977547234 yes 0 5.05876781757472 Other Tumor Driver PMID:33016924 mRNA vaccine induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer +NDDR-RP96B6V4BF-X ONOD4DCC Skin Skin Cutaneous Melanoma ERBB2 SNV p.H197Y 8 ALIHHNTYL ALIHHNTHL 9 17 39715843 C T HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.058 0.2 0.007 0.6004392 1.358 0.958901 -0.759838555 no 1 2.7079102909912973 Other Tumor Driver PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-QSCW08XXWJ-0 ONOD4DCC Skin Skin Cutaneous Melanoma COL18A1 SNV p.S306F 7 LLGVKLFGV LLGVKLSGV 9 HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.452 0.8 0.339 0.39031768 0.042 0.915367 -0.475244298 no 0 4.191604908313973 PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-3WX67JTZB5-G ONOD4DCC Skin Skin Cutaneous Melanoma TEAD1 SNV p.L209F 9 SVLENFTIFL SVLENFTILL 10 11 12930323 A T HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 1.119 1.9 0.083 0.22353907 1.174 0.967589 -0.077358142 no 1 3.555239427242588 PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-3FZN4MKTRM-3 ONOD4DCC Skin Skin Cutaneous Melanoma TEAD1 SNV p.L209F 8 VLENFTIFLV VLENFTILLV 10 11 12930323 A T HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 2.259 0.7 0.1 0.5003603 0.078 0.884139 -0.022758094 no 1 3.555239427242588 PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-3XTZVS0C4T-A 5K3HKC6D Skin Skin Cutaneous Melanoma NSDHL SNV p.A290V 9 ILTGLNYEV ILTGLNYEA 9 X 152868863 C T HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.067 0.17 0.028 0.57955974 0.218 0.562207 -2.354922618 no 1 3.800138646972027 PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-6JWME6V17H-Z Y3BFVLAR Skin Skin Cutaneous Melanoma GANAB SNV p.S184F 5 ALYGFVPVL ALYGSVPVL 9 11 62632668 G A HLA-A02:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.022 0.4 0.007 0.6907953 1.594 0.973129 -0.167054085 no 1 6.979636638529511 PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-PKEAHAWX4S-9 J6KE3KIV Skin Skin Cutaneous Melanoma TRIP12 SNV p.F1544S 2 PSDTRQMLFY PFDTRQMLFY 10 2 229787644 A G HLA-A01:01 CD8 multimer patient_TIL peptide_pulsed_APC none 0.036 0.09 0.022 0.39014745 2.326 0.544087 -3.218875825 no 1 3.995384355392576 PMID:26389673 Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes +NDDR-CZRBXE09Z4-F HVWWYCPV Stomach Gastric Cancer CYP2A6 SNV p.N438Y 3 KRYCFGEGL KRNCFGEGL 9 HLA-B14:02 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 1.536 0.15 0.296 0.19199942 1.8 0.56948 -0.78721369 no 0 -3.5454031892926263 Other Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-NYC0KZGC6A-S HVWWYCPV Stomach Gastric Cancer CYP2A6 SNV p.N438Y 3 KRYCFGEGL KRNCFGEGL 9 HLA-C07:04 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 2.72 18 7.923 0.05841868 1.8 0.56948 0.126413925 no 0 -3.5454031892926263 Other Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-4FDB71EDHG-Y M4XLJUGS Uterus Endometrial Cancer KRAS SNV p.G12C 5 VVGACGVGK VVGAGGVGK 9 HLA-A11:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 0.676 0.6 0.284 0.10408942 0.308 0.49574 1.15490091 no 1 2.6672328924875006 Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-0FHEYJAFS7-I DZZUH7EK Pancreas Pancreatic Adenocarcinoma (PDAC) TP53 SNV p.V25G 2 RGRAMAIYK RVRAMAIYK 9 HLA-A30:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 0.021 0.03 0.024 0.2952876 0.574 0.656203 1.945910149 no 0 3.101902155953119 Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-AT9B4Z8C95-G SFB6K5FA Pancreas Pancreatic Adenocarcinoma (PDAC) KRAS SNV p.G12V 8 KLVVVGAVGV KLVVVGAGGV 10 1 114716126 C A HLA-A02:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 2.879 1.3 1.036 0.51598555 0.63 0.35561 -0.74854804 no 1 3.0308304301532742 Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-4TAAMCST6Y-F SYIVONAA Thymus Thymoma CDC73 SNV p.Q254E 7 NIFAILESV NIFAILQSV 9 HLA-A02:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 0.247 0.9 0.077 0.41550258 0.894 0.963731 0.427983972 no 0 2.065791145294461 Other Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-N6HR7DRVC2-D EZJCG5SK Lung Lung Cancer KRAS SNV p.G12A 5 VVGAAGVGK VVGAGGVGK 9 HLA-A11:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 0.206 0.6 0.219 0.08056308 0.308 0.49574 -0.033415997 no 1 3.247616066270549 Other Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-3G50Q8D15Z-G D4OVDCY4 Pancreas Pancreatic Adenocarcinoma (PDAC) KRAS SNV p.G12D 5 VVGADGVGK VVGAGGVGK 9 HLA-A11:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 0.452 1.2 0.229 0.05571235 0.308 0.49574 0.752390014 no 1 3.0308304301532742 Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-P9VVWP3AAQ-7 47LXN6PR Pancreas Pancreatic Adenocarcinoma (PDAC) KRAS SNV p.G12V 5 VVGAVGVGK VVGAGGVGK 9 HLA-A11:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 0.128 0.5 0.076 0.22968939 0.308 0.49574 -0.509261902 no 1 3.0308304301532742 Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-8WT94E5KH5-G GXEZJAFU Pancreas Pancreatic Adenocarcinoma (PDAC) KRAS SNV p.G12D 8 KLVVVGADGV KLVVVGAGGV 10 12 25245350 C T HLA-A02:01 CD8 ELISPOT PBMC_pre "peptide_pulsed_APC, TMC_minigene" none 5.155 2.5 2.765 0.30073658 0.63 0.35561 -0.166023934 no 1 3.0308304301532742 Tumor Driver PMID:30835255 Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors +NDDR-76CBJC44KN-4 AMBE3DOP Blood/Bone marrow Chronic Lymphocytic Leukemia C6ORF89 SNV p.Y318C 10 MPIEPGDIGC MPIEPGDIGY 10 HLA-B35:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 1.739 0.9 0.783 0.65973526 -0.4 0.845155 4.822008185 yes 1 3.5961957207627404 PMID:24891321 Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia +NDDR-C06RNEZ45R-8 AMBE3DOP Blood/Bone marrow Chronic Lymphocytic Leukemia ALMS1 SNV p.G1001S 7 TPTVPSSSF TPTVPSGSF 9 2 73449528 G A HLA-B35:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.032 0.7 0.039 0.14113191 1.858 0.977371 -1.188224447 yes 1 2.501133376060947 Other Tumor Driver PMID:24891321 Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia +NDDR-5S8F797ZQ0-B V4UEFDFP Blood/Bone marrow Chronic Lymphocytic Leukemia FNDC3B SNV p.L294M 3 VVMSWAPPV VVLSWAPPV 9 3 172295393 T A HLA-A02:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.435 0.05 1.3 0.37867132 0.614 0.947741 -0.359200488 no 1 4.124237136458928 Other Tumor Driver PMID:24891321 Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia +NDDR-R061VV3SA3-E 7KQJQFYF Colon/Rectum Colorectal Adenocarcinoma AKT1 SNV p.E17K 1 KYIKTWRPRYF EYIKTWRPRYF 11 14 104780214 C T HLA-A23:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "tumor_cells, peptide_pulsed_APC" endogenous(HLA-block) 0.134 0.08 0.731 0.21049616 2.984 0.606498 -0.578623752 no 1 3.481712259170993 Tumor Driver PMID:30841906 Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 +NDDR-0ADS7G1KFJ-0 IKJKM6CH Lung Non-Small Cell Lung Cancer (NSCLC) BRAF SNV p.N581I 2 NIIFLHEDLTV NNIFLHEDLTV 11 7 140753393 T A HLA-A02:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "tumor_cells, peptide_pulsed_APC" endogenous(HLA-block) 5.797 5.5 1.733 0.19390954 0.808 0.804862 -1.275639345 no 0 0.5641331742871212 Tumor Driver PMID:30841906 Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 +NDDR-NADW9979N0-B YE643ISX Ovary Ovarian Cancer (epithelial) IL27RA SNV p.P594L 6 EEMEPLPVM EEMEPPPVM 9 19 14052160 C T HLA-B44:03 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.048 1.2 0.079 0.18478033 0.072 0.972839 0.344840486 yes 0 2.190393619472398 PMID:31221207 Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer +NDDR-2D8VM6B57P-6 7U4C6SW6 Ovary Ovarian Cancer (epithelial) CCR6 SNV p.V67L 4 FGLLGNILLVI FGLVGNILLVI 11 6 167136429 G C HLA-A02:24 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 3.985 13 6.659 0.44010946 0.108 -0.667346677 no 0 -7.828280760912152 PMID:31221207 Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer +NDDR-1PA1KV8VFV-C 7U4C6SW6 Ovary Ovarian Cancer (epithelial) FCGBP SNV p.A1177V 2 FVLSGESCLPL FALSGESCLPL 11 HLA-A02:06 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 2.749 0.8 2.226 0.11389381 0.856 0.935466 -1.108986326 no 0 1.3802861561230784 PMID:31221207 Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer +NDDR-25ES7DSS0P-6 7U4C6SW6 Ovary Ovarian Cancer (epithelial) TRPC4 SNV p.G577V 9 QSLFWSIFV QSLFWSIFG 9 13 37655242 C A HLA-A69:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" endogenous(HLA-block) 0.432 2.5 0.095 0.18444404 0.296 0.026861 -4.502891337 yes 0 -4.636660688370521 PMID:31221207 Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer +NDDR-YE0KNS4DEP-6 U2DXRUJY Skin Skin Cutaneous Melanoma ATR SNV p.S296L 8 KLYEEPLLK KLYEEPLSK 9 3 142562515 G A HLA-A03:01 CD8 "ELISPOT, ICS, multimer" "patient_TIL, PBMC_pre, PBMC_postVax" "peptide_pulsed_APC, tumor_cells" "endogenous(HLA-block), TMC" 0.001 0.01 0.001 0.5631237 0.998 0.932912 0 no 1 0.2944289114832716 Tumor Driver PMID:24043743 Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive Melanoma +NDDR-MK3JG6S0PH-Z OZBCLZO4 Lung Non-Small Cell Lung Cancer (NSCLC) EGFR SNV p.T790M 3 LIMQLMPFGCL LITQLMPFGCL 11 7 55181378 C T HLA-A02:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_Tc_line, healthy_donor_PBMC" peptide_pulsed_APC endogenous(HLA-block) 10.886 3.5 5.825 0.14237472 1.254 0.366241 -0.669490913 no 1 3.9243374515578378 Tumor Driver PMID:24223798 EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation +NDDR-AKP23P0HMV-C OZBCLZO4 Lung Non-Small Cell Lung Cancer (NSCLC) EGFR SNV p.T790M 1 MQLMPFGCLL TQLMPFGCLL 10 7 55181378 C T HLA-A02:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, patient_Tc_line, healthy_donor_PBMC" peptide_pulsed_APC endogenous(HLA-block) 2.973 6.5 4.315 0.24933057 1.232 0.957875 -0.02294365 no 1 3.9243374515578378 Tumor Driver PMID:24223798 EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation +NDDR-QS7NRQ41FQ-7 XYLTPHZM Skin Skin Cutaneous Melanoma MMS22L SNV p.S437F 10 EYYSKNLNSF EYYSKNLNSS 10 6 97231645 G A HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.068 0.8 0.482 0.38734272 2.684 0.0462 -5.107192468 no 0 -0.7602358908480553 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-NX70ZZP0CP-6 MILOVCNS Skin Skin Cutaneous Melanoma HERPUD1 SNV p.G161S 8 GLGPGFSSY GLGPGFSGY 9 16 56939286 G A HLA-B15:01 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.022 0.4 0.021 0.09945778 2.496 0.963264 -1.984131362 no 0 4.4519363984538245 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-HG03BBJD3N-4 4RMAUA5K Skin Skin Cutaneous Melanoma PRDM10 SNV p.S1050F 9 TYLPSAWNF TYLPSAWNS 9 11 129910529 G A HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.002 0.01 0.014 0.62892807 2.7 0.064137 -7.095478885 no 0 0.6235832374351025 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-T0Z17A2M22-D RUNCUPXH Skin Skin Cutaneous Melanoma PRDM10 SNV p.S1050F 9 TYLPSAWNFF TYLPSAWNSF 10 11 129910529 G A HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.009 0.03 0.038 0.47059944 2.7 0.957051 0.251314428 no 0 0.6235832374351025 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-AHDSK0DNZH-Z ATSSHWMT Skin Skin Cutaneous Melanoma INSIG1 SNV p.S238F 6 VYQYTFPDF VYQYTSPDF 9 7 155302755 C T HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.021 0.12 0.002 0.4353292 2.674 0.200933 -0.566395475 no 0 3.4989312813161737 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-GFP4PGXK3P-6 P3V3F57E Skin Skin Cutaneous Melanoma INSIG1 SNV p.S238F 6 VYQYTFPDFL VYQYTSPDFL 10 7 155302755 C T HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.45 0.3 0.078 0.3607351 1.094 0.480538 0.083381609 no 0 3.4989312813161737 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-GGGN8GD973-E SLHIGIK4 Skin Skin Cutaneous Melanoma INSIG1 SNV p.S238F 5 YQYTFPDF YQYTSPDF 8 7 155302755 C T HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 2.1 7.5 9.398 0.08030745 2.974 0.200933 -0.44895022 no 0 3.4989312813161737 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-0TX1EYJWDC-U CAQZ3K3K Skin Skin Cutaneous Melanoma INSIG1 SNV p.S238F 5 YQYTFPDFLY YQYTSPDFLY 10 7 155302755 C T HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 1.647 12 1.474 0.012628782 3.364 0.96755 0.392795255 no 0 3.4989312813161737 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-0CP0AVXH3A-S BBZ33E2J Skin Skin Cutaneous Melanoma MMS22L SNV p.S437F 8 YSKNLNSFF YSKNLNSSF 9 HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 2.402 3.5 0.93 0.030581463 2.47 0.911966 0.087844363 no 0 -0.7602358908480553 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-F4N0FN189Q-7 VX46FFYO Skin Skin Cutaneous Melanoma MMS22L SNV p.S437F 9 YYSKNLNSF YYSKNLNSS 9 6 97231645 G A HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.003 0.06 0.007 0.40572074 2.532 0.0462 -7.35372233 no 0 -0.7602358908480553 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-8DJBG1WJ00-B KX4N5RSA Skin Skin Cutaneous Melanoma MMS22L SNV p.S437F 9 YYSKNLNSFF YYSKNLNSSF 10 6 97231645 G A HLA-A24:02 CD8 "ELISPOT, ICS" PBMC_pre "peptide_pulsed_APC, tumor_cells, cDNA_cell_line" endogenous(HLA-block) 0.031 0.04 0.057 0.32852235 2.532 0.911966 -0.121360857 no 0 -0.7602358908480553 PMID:28423700 HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model +NDDR-2XV4D1HBF7-I NBE6WCJN Ovary Ovarian Cancer DPY19L4 SNV p.L143F 5 LYPEFIASI LYPELIASI 9 8 94739496 C T HLA-A24:02 CD8 "ELISPOT, ICS" "healthy_donor_PBMC, PBMC_pre, patient_Tc_line, TCR_clone" "peptide_pulsed_APC, cDNA_cell_line" endogenous(HLA-block) 0.05 0.05 0.009 0.31107822 0.71 0.933351 0.105360516 no 0 2.3199358007315727 PMID:29541393 Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells +NDDR-9G5GW03V3V-C PC7T4K3B Ovary Ovarian Cancer RNF19B SNV p.V372L 2 MLIGIPVYV MVIGIPVYV 9 1 32946434 C G HLA-A02:01 CD8 "ELISPOT, ICS" "healthy_donor_PBMC, PBMC_pre, patient_Tc_line, TCR_clone" "peptide_pulsed_APC, cDNA_cell_line" endogenous(HLA-block) 0.015 0.09 0.006 0.7612357 0.482 0.811435 -1.402823663 no 0 4.1546966138277375 PMID:29541393 Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells +NDDR-T8XPXGAW5J-0 ZEWNQSDP Skin Skin Cutaneous Melanoma MED15 SNV p.P677S 4 DANSFLQSV DANPFLQSV 9 22 20586576 C T HLA-B51:01 CD8 "ELISPOT, ICS" "PBMC_pre, patient_Tc_line" "peptide_pulsed_APC, tumor_cells" "MS, endogenous(HLA-block)" 0.01 4 0.001 0.8711061 -0.126 0.965305 0.510825624 yes 0 4.421583505080367 PMID:26819371 Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens +NDDR-97N3S6RFMR-8 FKQHULMK Adrenal/Sympathetic nervous system Neuroblastoma ALK SNV p.R1275Q 2 AQDIYRASY ARDIYRASY 9 2 29209798 C T HLA-B15:01 CD8 multimer healthy_donor_PBMC peptide_pulsed_APC endogenous(HLA-block) 0.116 1.6 0.066 0.7444982 3.05 0.975322 -3.547683294 no 1 Tumor Driver PMID:29441070 A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations +NDDR-1KM1369VHT-A FS2BPVBA Adrenal/Sympathetic nervous system Neuroblastoma ALK SNV p.R1275Q 2 AQDIYRASYY ARDIYRASYY 10 2 29209798 C T HLA-B15:01 CD8 multimer healthy_donor_PBMC peptide_pulsed_APC endogenous(HLA-block) 0.273 2.5 0.548 0.6774427 3.05 0.755054 -3.326036916 no 1 Tumor Driver PMID:29441070 A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations +NDDR-EH6J52GFPR-8 BRC35DEQ Skin Skin Cutaneous Melanoma ETV6 SNV p.L340V 1 VLWDYVYQL LLWDYVYQL 9 6 36369063 G C HLA-A02:01 CD8 HLA-block patient_TIL peptide_pulsed_APC MS 0.004 0.06 0.001 0.8043776 1.35 0.9792 -0.559615788 no 1 2.839596604861465 Other Tumor Driver PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-T74Q80PSFJ-0 BRC35DEQ Skin Skin Cutaneous Melanoma ETV6 SNV p.L340V 1 VLWDYVYQLL LLWDYVYQLL 10 6 36369063 G C HLA-A02:01 CD8 "HLA-block, multimer, CD107a" patient_TIL peptide_pulsed_APC none 0.213 0.3 0.125 0.60489655 1.35 0.721166 -0.493779756 no 1 2.839596604861465 Other Tumor Driver PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-Q7H8S9E5T3-E 7BEVRZEZ Skin Skin Cutaneous Melanoma WDR75 SNV p.S749F 1 FMFVNSLLL SMFVNSLLL 9 2 189474766 C T HLA-A02:01 CD8 "HLA-block, multimer, CD107a" patient_TIL peptide_pulsed_APC none 0.237 0.6 0.485 0.4168099 1.036 0.973897 -0.843674668 no 1 3.139877612000268 PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-117KNP89MY-F 7BEVRZEZ Skin Skin Cutaneous Melanoma KDELR2 SNV p.T121I 4 ILWIFSIYL ILWTFSIYL 9 22 38481222 C T HLA-A02:01 CD8 "HLA-block, multimer, CD107a" patient_TIL peptide_pulsed_APC none 0.532 0.4 0.019 0.6383039 1.274 0.978254 1.505958865 no 0 6.081459702108129 PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-KH4CV1H7MW-D 7BEVRZEZ Skin Skin Cutaneous Melanoma MYLIP SNV p.P8L 2 RLDAVLMEV RPDAVLMEV 9 6 16129345 C T HLA-A02:01 CD8 "HLA-block, multimer, CD107a" patient_TIL peptide_pulsed_APC none 0.022 0.01 0.007 0.6539008 0.184 0.969844 -5.545709973 no 1 3.914406540292237 PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-MC9PF0RRZ9-K 7BEVRZEZ Skin Skin Cutaneous Melanoma SVIL SNV p.E2183K 5 YLTDKDFEFA YLTDEDFEFA 10 10 29458445 C T HLA-A02:01 CD8 "HLA-block, multimer, CD107a" patient_TIL peptide_pulsed_APC none 0.654 1.2 0.314 0.32436848 -0.754 0.077108 -0.223754985 no 1 2.481725171677818 PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-KBBNZ0V0YJ-0 7BEVRZEZ Skin Skin Cutaneous Melanoma CCT4 SNV p.S115F 1 FLLDSCTKL SLLDSCTKL 9 HLA-A02:01 CD8 HLA-block patient_TIL peptide_pulsed_APC MS 0.03 0.07 0.034 0.6819849 0.738 0.978012 -1.029619417 no 1 5.646922116939426 PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-HFYS7GCRJP-6 BRC35DEQ Skin Skin Cutaneous Melanoma NUP210 SNV p.S427F 8 AIDAALTFV AIDAALTSV 9 3 13376304 G A HLA-A02:01 CD8 "HLA-block, multimer, CD107a" patient_TIL peptide_pulsed_APC none 0.33 0.7 0.021 0.5289944 0.344 0.833869 0.681098842 no 1 3.3153894563534725 PMID:31921104 Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display +NDDR-AM42KWVSZE-W YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma ADARB1 SNV p.S430F 1 FLLRFLYTQL SLLRFLYTQL 10 21 45182711 C T HLA-A02:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 1.027 0.4 0.193 0.42023903 0.738 0.968085 -0.090251821 no 0 1.883327472971322 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-NHGGDAJ686-H YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma SLC25A19 SNV p.G190R 10 TLIAIFPYARL TLIAIFPYAGL 11 17 75277388 C T HLA-A02:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.749 2.5 1.817 0.22553797 1.07 0.96574 -0.02336975 no 0 0.6382125876388375 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-BAGKSM08VC-U YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma PCDH8 SNV p.R940H 4 SPPHPGRLPDL SPPRPGRLPDL 11 13 52844663 C T HLA-B07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.469 1.5 0.58 0.04200774 0.408 0.964318 -0.079878679 no 0 -9.965784284662089 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-Q973S97QZX-E YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma PARP4 SNV p.T1170I 7 KENSLIIQF KENSLITQF 9 13 24442624 G A HLA-B18:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.058 0.25 0.012 0.5344325 2.52 0.45129 -0.066691374 no 0 4.176241693524634 Other Tumor Driver PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-ANQGPTE9P1-C YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma RAB39B SNV p.W5R 5 MEAIRLYQF MEAIWLYQF 9 X 155264276 A T HLA-B18:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.053 0.03 0.006 0.7067172 2.612 0.741549 -0.140581951 no 0 -1.3580841439264495 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-Z7CCYG5QGE-W YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma SLC25A19 SNV p.G190R 2 ARLQFSCYSSL AGLQFSCYSSL 11 17 75277388 C T HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 4.939 9.5 4.987 0.22069205 1.568 0.700563 -1.948625344 no 0 0.6382125876388375 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-ZC27261938-J YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma ZNF567 SNV p.V575L 9 FRQKTNLIL FRQKTNLIV 9 19 36720540 G C HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.074 4.5 0.092 0.7459626 0.95 0.825615 -2.009482953 no 0 0.2979540847343163 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-M9AGD63GT5-G YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma RAB39B SNV p.W5R 2 IRLYQFRLIV IWLYQFRLIV 10 X 155264276 A T HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 10.326 28 4.299 0.655081 0.638 0.670805 -1.028311182 no 0 -1.3580841439264495 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-4EJYN1WKM2-D YJOSS4J7 Kidney Clear Cell Renal Cell Carcinoma RAB39B SNV p.W5R 2 IRLYQFRLIVI IWLYQFRLIVI 11 X 155264276 A T HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 20.391 28 2.646 0.25817725 0.858 0.6358 -0.352202203 no 0 -1.3580841439264495 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-TEFPFSQZHF-X OAF52DHL Kidney Clear Cell Renal Cell Carcinoma NEK10 SNV p.D145Y 11 VLICLRLLMRY VLICLRLLMRD 11 3 27322191 C A HLA-B15:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 5.92 1.4 2.951 0.03162649 3.114 0.024991 -2.721473221 no 0 -3.399732054369197 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-FE4XSYS8S3-E OAF52DHL Kidney Clear Cell Renal Cell Carcinoma CTSF SNV p.T246S 3 FRSIYLNTLL FRTIYLNTLL 10 11 66566152 G C HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 1.699 7 0.398 0.7893434 1.006 0.849469 -0.199439267 no 0 4.256249630145267 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-EK1K8GPQ5W-D OAF52DHL Kidney Clear Cell Renal Cell Carcinoma PRKAR2A SNV p.L187I 3 LYIWFKTACL LYLWFKTACL 10 HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 4.929 11 5.32 0.61311805 1.298 -0.332027979 no 0 2.854514364166717 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-7GPH5H00GS-9 OAF52DHL Kidney Clear Cell Renal Cell Carcinoma ARHGAP28 SNV p.K412E 3 MLEYQKILWKV MLKYQKILWKV 11 18 6890062 A G HLA-A02:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.986 2 7.585 0.16750674 0.056 0.856781 -0.018580495 no 0 0.3371934800710375 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-NZJXQC4WSN-4 OAF52DHL Kidney Clear Cell Renal Cell Carcinoma PRKAR2A SNV p.L187I 6 TQFLYIWFK TQFLYLWFK 9 HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.354 1.5 0.009 0.5190069 0.878 -0.233261681 no 0 2.854514364166717 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-4WVHS0EVSF-X OAF52DHL Kidney Clear Cell Renal Cell Carcinoma GDF5 SNV p.K349R 10 ALFLVFGRTRK ALFLVFGRTKK 11 20 35434369 T C HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 1.475 0.7 1.087 0.12049223 0.954 0.803062 0.221450071 no 0 -5.066127282219316 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-N7NFDNFWFW-D OAF52DHL Kidney Clear Cell Renal Cell Carcinoma ARHGAP28 SNV p.K412E 8 HIIRLMLEY HIIRLMLKY 9 18 6890062 A G HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.9 14 1.554 0.05545967 3.09 0.851749 -0.129077042 no 0 0.3371934800710375 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-6N18E4N5PH-Z OAF52DHL Kidney Clear Cell Renal Cell Carcinoma C20orf27 SNV p.C156Y 3 GTYVRVTVQAR GTCVRVTVQAR 11 HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.443 1.2 2.36 0.12911811 1.782 -0.77730622 no 0 3.868597856901992 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-BDK1XB68PD-V OAF52DHL Kidney Clear Cell Renal Cell Carcinoma ARHGAP28 SNV p.K412E 4 LMLEYQKILWK LMLKYQKILWK 11 18 6890062 A G HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 5.117 3.5 3.175 0.14340997 0.664 0.218072 -0.056419861 no 0 0.3371934800710375 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-8K66P64TP3-E OAF52DHL Kidney Clear Cell Renal Cell Carcinoma F2RL2 SNV p.K67T 9 WTGATITVTIK WTGATITVKIK 11 5 76618507 T G HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 4.789 2.5 1.401 0.1520231 0.01 0.721694 -0.009973072 no 0 -1.3045540957015431 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-NYQHAVZB74-F OAF52DHL Kidney Clear Cell Renal Cell Carcinoma MPO SNV p.R421W 6 HTLLLWEHNR HTLLLREHNR 10 17 58275646 G A HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 3.368 3 2.325 0.2546191 1.458 0.331341 -0.083963387 no 0 -4.490050853695689 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-JYCMSZZQE9-K OAF52DHL Kidney Clear Cell Renal Cell Carcinoma ARHGAP28 SNV p.K412E 3 MLEYQKILWK MLKYQKILWK 10 18 6890062 A G HLA-A11:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.304 5.5 6.766 0.2211914 0.206 0.218072 -0.034133006 no 0 0.3371934800710375 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-G7TBC3QRHS-9 OAF52DHL Kidney Clear Cell Renal Cell Carcinoma C20orf27 SNV p.C156Y 1 YVRVTVQARVM CVRVTVQARVM 11 HLA-B07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 5.083 0.5 3.543 0.020636627 0.374 -1.297797432 no 0 3.868597856901992 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-D85SAX278W-D IAXGKPRY Kidney Clear Cell Renal Cell Carcinoma OR4C6 SNV p.S50C 3 ITCQSLRSPMY ITSQSLRSPMY 11 11 55665314 A T HLA-A01:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.918 0.03 1.948 0.009559649 2.944 0.900234 0.884661186 no 0 -9.965784284662089 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-V7HHKJBHX0-B IAXGKPRY Kidney Clear Cell Renal Cell Carcinoma FZD6 SNV p.P30A 4 ITVARCMKMAY ITVPRCMKMAY 11 8 103300195 C G HLA-A01:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.998 0.15 1.958 0.0441262 3.082 0.757996 0.758620094 no 0 3.163703529564198 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-KPAPP08JZN-4 IAXGKPRY Kidney Clear Cell Renal Cell Carcinoma TEAD2 SNV p.L407Q 7 YMMNSVQENF YMMNSVLENF 10 12 3040237 T A HLA-B44:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 9.908 5 6.214 0.04993693 2.628 0.195404 -0.378942333 no 0 2.498187423666854 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-H269NY9Y4N-4 IAXGKPRY Kidney Clear Cell Renal Cell Carcinoma OR5K3 SNV p.I208M 3 IQMFTIVLVSY IQIFTIVLVSY 11 3 98391289 C G HLA-B44:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 12.817 0.4 1.108 0.008547084 3.242 0.855517 -0.051102124 no 0 -9.965784284662089 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-PMTES560GN-4 IAXGKPRY Kidney Clear Cell Renal Cell Carcinoma YOD1 SNV p.S9L 9 METLHIIYLEA METLHIIYSEA 11 1 207052210 G A HLA-B44:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 13.223 9 2.941 0.030333834 -0.564 -0.023912071 no 0 0.7847117769866219 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-JDV9ZVKS42-D IAXGKPRY Kidney Clear Cell Renal Cell Carcinoma ERCC8 SNV p.G221V 6 VRRASVCLITL VRRASGCLITL 11 5 60899683 C A HLA-C07:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 3.521 12 3.976 0.10584346 1.416 0.918339 0.165145293 no 0 -0.3725801240538413 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-G3BE79QGN2-D BOGIVUKN Kidney Clear Cell Renal Cell Carcinoma GLG1 SNV p.L338I 6 RVYKCIFNH RVYKCLFNH 9 16 74494798 G T HLA-A03:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.249 0.5 0.008 0.39178392 0.178 0.097848 -0.337619026 no 0 4.478185491730762 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-YYZ3HZCGF7-I BOGIVUKN Kidney Clear Cell Renal Cell Carcinoma GLG1 SNV p.L338I 6 RVYKCIFNHK RVYKCLFNHK 10 16 74494798 G T HLA-A03:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.056 0.01 0.004 0.68185747 1.178 0.961058 -0.356674944 no 0 4.478185491730762 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-M8B2NH5486-H BOGIVUKN Kidney Clear Cell Renal Cell Carcinoma SRD5A2 SNV p.A217T 7 LPALAFTFFSL LPALAFAFFSL 11 2 31529356 C T HLA-B07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.672 0.2 0.14 0.08084268 0.46 0.971422 -0.418279478 no 0 -5.8489265178067225 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-82P7M58FXX-E BOGIVUKN Kidney Clear Cell Renal Cell Carcinoma CD1C SNV p.V311M 1 MPLVILIVL VPLVILIVL 9 1 158293253 G A HLA-B07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.586 0.9 0.017 0.7926122 0.438 0.917668 -0.00170503 no 0 -0.9160941974071436 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-6TCSWHS4A6-H BOGIVUKN Kidney Clear Cell Renal Cell Carcinoma CD1C SNV p.V311M 1 MPLVILIVLVL VPLVILIVLVL 11 1 158293253 G A HLA-B07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 4.057 0.9 0.853 0.116057985 0.438 0.883395 -0.074319225 no 0 -0.9160941974071436 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-5ECRJQSBEH-Z HRJPSEJN Kidney Clear Cell Renal Cell Carcinoma ABCC12 SNV p.Q663K 1 KFLESCDEVI QFLESCDEVI 10 16 48115417 G T HLA-A24:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 4.435 1.3 2.46 0.05148891 0.838 0.231093 -0.548310376 no 0 -9.965784284662089 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-0WQ2MP5DZM-3 HRJPSEJN Kidney Clear Cell Renal Cell Carcinoma PCDH11X SNV p.V471I 7 VFTQSFITVSI VFTQSFVTVSI 11 X 91877651 G A HLA-A24:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 3.251 1 2.133 0.03491083 0.622 0.920262 0.089727514 no 0 -8.702749878828293 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-55NKH7X9AM-3 HRJPSEJN Kidney Clear Cell Renal Cell Carcinoma KCNA10 SNV p.V324F 10 YFATLITELF YFATLITELV 10 1 110517818 C A HLA-C04:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.709 2.5 0.213 0.5196818 2.53 0.965234 -1.027745596 no 0 -9.965784284662089 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-1X2QPD84BC-U HRJPSEJN Kidney Clear Cell Renal Cell Carcinoma GYS1 SNV p.D219Y 8 YLCAGAVYF YLCAGAVDF 9 19 48985873 C A HLA-C04:01 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 2.729 7.5 0.937 0.11045939 2.406 0.613652 -0.708059259 no 0 4.514850523982965 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-6YS6KZF0ZJ-0 CWS5ZPHH Kidney Clear Cell Renal Cell Carcinoma SAMD9 SNV p.V853L 7 IPDSIALIQQL IPDSIAVIQQL 11 7 93103541 C G HLA-B07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.785 1.8 0.721 0.1560137 -0.004 0.939483 0.020592748 no 0 2.005937758649707 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-XRN8FZGYB9-K CWS5ZPHH Kidney Clear Cell Renal Cell Carcinoma FAM46D SNV p.G140R 2 NRHDCWSLISL NGHDCWSLISL 11 X 80442957 G A HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 1.435 7.5 1.437 0.38482612 1.566 -2.943888672 no 0 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-86Q5CKJV2V-C CWS5ZPHH Kidney Clear Cell Renal Cell Carcinoma TMEM14B SNV p.S48L 7 GRQSWSLYV GRQSWSSYV 9 6 10756495 C T HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 0.943 28 0.711 0.6849103 0.46 -0.809633276 no 0 2.6366708870508737 Other Tumor Driver PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-35E95E8DZT-A CWS5ZPHH Kidney Clear Cell Renal Cell Carcinoma ATP5L SNV p.E37D 8 FWYYAKVDL FWYYAKVEL 9 11 118406995 G C HLA-C07:02 CD8 "ELISPOT, ICS, multimer" patient_Tc_line "peptide_pulsed_APC, tumor_cells" none 1.287 5 2.884 0.6691152 1.222 1.654737672 no 0 PMID:32226429 Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations +NDDR-TAN0D6MD3E-W N6KFWJQT Skin Skin Cutaneous Melanoma ZNF878 SNV p.T216A 10 ALSYLVSFQR ALSYLVSFQT 10 19 12044754 G C HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 0.864 1.8 0.924 0.08088384 1.742 0.268499 -3.411941921 no 0 -3.561495225707876 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-K21F4K6BFN-4 4AYY5TKK Skin Skin Cutaneous Melanoma IFT80 SNV p.H63Y 9 DDIYPIDFY DDIYPIDFH 9 3 160381575 G A HLA-A25:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 2.71 15 2.041 0.014567288 2.476 0.031321 -1.979294962 no 0 0.6151337575144284 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-TB0YN7HNPM-3 EC43Q54U Skin Skin Cutaneous Melanoma PTPRU SNV p.P783L 9 DHYAYSYYL DHYAYSYYP 9 1 29289712 C T HLA-C06:02 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 1.063 32 0.426 0.033498265 0.96 0.047113 -3.101210374 no 0 0.9139071064582698 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-KZB4CT37FG-Y BJGJ7IRT Skin Skin Cutaneous Melanoma PRICKLE3 SNV p.E566K 1 KRIPLPPHLC ERIPLPPHLC 10 X 49175825 C T HLA-C06:02 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 1.568 34 2.369 0.047567155 0.624 0.048856 -0.456035352 no 0 1.906736681459138 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-E4C0EFBDYG-Y B5DYJLWE Skin Skin Cutaneous Melanoma IQCF2 SNV p.A66V 9 LVRRTLLHV LVRRTLLHA 9 3 51874079 G A HLA-C15:02 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 1.337 4 0.435 0.012773356 0.584 0.267439 -1.746888317 no 0 -9.965784284662089 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-DPWR40BZ71-C 5UPLPDEU Skin Skin Cutaneous Melanoma IPO8 SNV p.S357F 9 NISEDVIFF NISEDVIFS 9 12 30669257 G A HLA-A25:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 0.294 4 0.44 0.001440531 2.882 0.030009 -4.614210829 no 0 3.321793844815637 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-7RGBS210TA-S GNOPTMJG Skin Skin Cutaneous Melanoma B4GALNT3 SNV p.M544V 8 PVKNLPQV PVKNLPQM 8 12 553553 A G HLA-B51:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 1.043 18 44.895 0.35037833 0.096 0.97563 -1.179023687 yes 0 1.239090613533076 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-WVB22RGYC4-F N6KFWJQT Skin Skin Cutaneous Melanoma TRIOBP SNV p.S826T 11 RTSSTQQDNPK RTSSTQQDNPQ 11 22 37725032 T A HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 0.297 0.12 1.911 0.017354071 0.704 0.106883 -3.408577489 no 0 3.3747612795662447 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF +NDDR-PZNWG95E5N-4 N6KFWJQT Skin Skin Cutaneous Melanoma PRICKLE3 SNV p.E566K 11 SSEDDGFFLGK SSEDDGFFLGE 11 X 49175825 C T HLA-A11:01 CD8 "ELISPOT, ICS, multimer" "PBMC_pre, PBMC_postVax" peptide_pulsed_APC none 0.715 1.7 0.622 0.17497762 0.328 0.092192 -3.631309602 no 0 1.906736681459138 PMID:32582212 Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF